var title_f3_59_4016="SLS MRI 5 16 35 months";
var content_f3_59_4016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Brain MRI (at 5, 16, and 35 months) of a patient with Sjogren-Larsson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 167px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted MR images (3100/98 [TR/TE]). There is a delay in the maturation of the white matter on all three images. Image A) At five months of age, the unmyelinated periventricular white matter shows no abnormal signal intensities. Images B and C) Images obtained at 16 (B) and 35 (C) months of age show nonprogressive, slight signal-intensity abnormalities in the periventricular white matter that mainly involve the occipital trigones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Willemsen, MA, Van Der, Graaf M, Van Der, Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &copy;2004 American Society of Neuroradiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4016=[""].join("\n");
var outline_f3_59_4016=null;
var title_f3_59_4017="Gross hematuria algorithm";
var content_f3_59_4017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Algorithm for gross or symptomatic microscopic hematuria in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 631px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Patel, HP, Bissler, JJ. Hematuria in children. Pediatr Clin North Am 2001; 48:1519. Copyright &copy;2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4017=[""].join("\n");
var outline_f3_59_4017=null;
var title_f3_59_4018="Attachment of stoma";
var content_f3_59_4018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Attachment of stoma at skin and fascia for colostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4018=[""].join("\n");
var outline_f3_59_4018=null;
var title_f3_59_4019="Patient information: Pregnancy in Rh-negative women (The Basics)";
var content_f3_59_4019=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87306\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/11/29874\">",
"         Patient information: Abortion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/57/42897\">",
"         Patient information: Amniocentesis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/46/39663\">",
"         Patient information: Chorionic villus sampling (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/20/35138\">",
"         Patient information: Ectopic pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/52/17218\">",
"         Patient information: Miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/29/37331\">",
"         Patient information: Prenatal care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/17/36113\">",
"         Patient information: Threatened miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/47/42739\">",
"         Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/28/14785\">",
"         Patient information: Amniocentesis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/7/2161\">",
"         Patient information: Chorionic villus sampling (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/43/38578\">",
"         Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/8/28803\">",
"         Patient information: Miscarriage (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pregnancy in Rh-negative women (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H596788325\">",
"      <span class=\"h1\">",
"       What does &ldquo;Rh-negative&rdquo; mean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Rh&rdquo; is the name of a protein found on red blood cells. People who have this protein have an &ldquo;Rh-positive&rdquo; blood type. People who do not have this protein have an &ldquo;Rh-negative&rdquo; blood type. Having an Rh-positive or Rh-negative blood type does not affect your health. But problems can happen during pregnancy if a woman has Rh-negative blood and her baby has Rh-positive blood.",
"     </p>",
"     <p>",
"      Luckily, there is a medicine that can prevent these problems most of the time.",
"     </p>",
"     <p>",
"      Women with Rh-positive blood do not have the problems discussed in this article.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H596788340\">",
"      <span class=\"h1\">",
"       How do I know my blood type?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will do blood tests at your first prenatal visit. This includes a test to check your blood type.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H596788355\">",
"      <span class=\"h1\">",
"       What problems can happen when a woman has Rh-negative blood?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Certain problems can happen when a woman has Rh-negative blood and the baby in her uterus (womb) has Rh-positive blood (",
"      <a class=\"graphic graphic_figure graphicRef82935 \" href=\"UTD.htm?7/20/7495\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Usually, during pregnancy, blood between the mother and baby does not mix. But sometimes it does, especially right after the baby is born. If a small amount of the baby's blood gets into the mother's blood vessels during delivery, the mother&rsquo;s immune (infection-fighting) system makes proteins called &ldquo;antibodies.&rdquo; In the woman&rsquo;s next pregnancy, these antibodies can cross the placenta and damage some of the next baby&rsquo;s red blood cells. This can cause a condition called anemia, which is when a person has too few red blood cells. If this happens, the baby can make more red blood cells, but sometimes not enough to prevent anemia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H596788389\">",
"      <span class=\"h1\">",
"       How do I know my baby&rsquo;s blood type?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes it&rsquo;s hard to know. If you know your baby&rsquo;s father&rsquo;s blood type, you might know your baby&rsquo;s blood type. If both you and the baby&rsquo;s father have Rh-negative blood, your baby will have Rh-negative blood.",
"     </p>",
"     <p>",
"      If your baby&rsquo;s father has Rh-positive blood, your baby could have Rh-negative or Rh-positive blood. But if you have Rh-negative blood, the doctor or midwife will treat your baby as if he or she has Rh-positive blood. That way, any possible problems can be prevented.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H596788406\">",
"      <span class=\"h1\">",
"       What happens next?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are Rh-negative, your doctor or midwife will do blood tests during pregnancy to check whether you have antibodies in your blood.",
"     </p>",
"     <p>",
"      If you do not have antibodies in your blood and your baby is (or could be) Rh-positive, your doctor or midwife will give you medicine. This medicine prevents your body from making antibodies that could attack your baby&rsquo;s red blood cells. This can prevent anemia or other problems.",
"     </p>",
"     <p>",
"      The medicine is called anti-D immune globulin (sample brand name: RhoGAM). It usually comes as a shot. You will get it during your third trimester.",
"     </p>",
"     <p>",
"      After your baby is born, the doctor will do a blood test to check your baby&rsquo;s blood type. If your baby is Rh-positive, your doctor will give you another dose of anti-D immune globulin soon after delivery. If your baby is Rh-negative, you do not need another dose.",
"     </p>",
"     <p>",
"      Women who are Rh-negative might also get anti-D immune globulin at other times. Doctors give this medicine to Rh-negative women if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleed during pregnancy",
"       </li>",
"       <li>",
"        Have a test during pregnancy called amniocentesis or chorionic villus sampling (CVS)",
"       </li>",
"       <li>",
"        Have a miscarriage, which is when a pregnancy ends on its own",
"       </li>",
"       <li>",
"        Have an abortion, which is when a woman ends a pregnancy",
"       </li>",
"       <li>",
"        Have an ectopic pregnancy, which is a pregnancy that grows in the wrong place in a woman&rsquo;s body",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H596788421\">",
"      <span class=\"h1\">",
"       What happens if I already have antibodies in my blood?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you already have antibodies in your blood, anti-D immune globulin will not help. Your doctor will not give you this medicine.",
"     </p>",
"     <p>",
"      But he or she will do different tests to monitor your baby during pregnancy. If anemia or other problems happen, he or she will talk with you about possible treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H596788436\">",
"      <span class=\"h1\">",
"       What if I get pregnant again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you get pregnant again, you will need treatment again. Rh-negative women are treated with anti-D immune globulin during each pregnancy, as long as they don&rsquo;t have antibodies in their blood.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H596788451\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"       Patient information: Prenatal care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=see_link\">",
"       Patient information: Amniocentesis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=see_link\">",
"       Patient information: Chorionic villus sampling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=see_link\">",
"       Patient information: Miscarriage (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=see_link\">",
"       Patient information: Threatened miscarriage (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=see_link\">",
"       Patient information: Abortion (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=see_link\">",
"       Patient information: Ectopic pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"       Patient information: Amniocentesis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=see_link\">",
"       Patient information: Chorionic villus sampling (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"       Patient information: Miscarriage (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=see_link\">",
"       Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=see_link\">",
"       Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/59/4019?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87306 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4019=[""].join("\n");
var outline_f3_59_4019=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788325\">",
"      What does &ldquo;Rh-negative&rdquo; mean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788340\">",
"      How do I know my blood type?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788355\">",
"      What problems can happen when a woman has Rh-negative blood?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788389\">",
"      How do I know my baby&rsquo;s blood type?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788406\">",
"      What happens next?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788421\">",
"      What happens if I already have antibodies in my blood?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788436\">",
"      What if I get pregnant again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H596788451\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=related_link\">",
"      Patient information: Abortion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=related_link\">",
"      Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=related_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=related_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=related_link\">",
"      Patient information: Chorionic villus sampling (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=related_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=related_link\">",
"      Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=related_link\">",
"      Patient information: Ectopic pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=related_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=related_link\">",
"      Patient information: Miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=related_link\">",
"      Patient information: Threatened miscarriage (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_59_4020="Epinephrine (adrenaline) (nasal): Patient drug information";
var content_f3_59_4020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline) (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/34/3620?source=see_link\">",
"     see \"Epinephrine (adrenaline) (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=see_link\">",
"     see \"Epinephrine (adrenaline) (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8084972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to epinephrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11669 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.14-B56043E255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4020=[""].join("\n");
var outline_f3_59_4020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090006\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031080\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031079\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031084\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031085\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031087\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031082\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031083\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031088\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031089\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/34/3620?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/24/10630?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/20/10568?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_59_4021="Ipratropium (oral inhalation): Pediatric drug information";
var content_f3_59_4021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ipratropium (oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36469?source=see_link\">",
"    see \"Ipratropium (oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/51/39732?source=see_link\">",
"    see \"Ipratropium (oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8120000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atrovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atrovent&reg; HFA;",
"     </li>",
"     <li>",
"      Gen-Ipratropium;",
"     </li>",
"     <li>",
"      Mylan-Ipratropium Sterinebs;",
"     </li>",
"     <li>",
"      Novo-Ipramide;",
"     </li>",
"     <li>",
"      Nu-Ipratropium;",
"     </li>",
"     <li>",
"      PMS-Ipratropium;",
"     </li>",
"     <li>",
"      Teva-Ipratropium Sterinebs",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nebulization: 25 mcg/kg/dose 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36469?source=see_link\">",
"      see \"Ipratropium (oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants: Nebulization: 125-250 mcg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acute exacerbation of asthma (has not been shown to provide further benefit once the patient is hospitalized; NIH guidelines, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Nebulization: 250-500 mcg (0.25-0.5 mg) every 20 minutes for 3 doses, then as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Metered inhaler: 4-8 puffs as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;12 years and Adults: Nebulization: 500 mcg (0.5 mg) every 30 minutes for 3 doses, then as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Metered inhaler: 8 puffs as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance treatments (nonacute) (evidence is lacking for providing added benefit to beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists in long-term control asthma therapy; NIH Guidelines, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nebulization: 250-500 mcg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Metered inhaler: 1-2 inhalations every 6 hours; not to exceed 12 inhalations/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nebulization: 250 mcg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Metered inhaler: 2-3 inhalations every 6 hours; not to exceed 12 inhalations/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8120136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as bromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrovent&reg; HFA: 17 mcg/actuation (12.9 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as bromide: 0.02% [500 mcg/2.5 mL] (25s, 30s, 60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as bromide [preservative free]: 0.02% [500 mcg/2.5 mL] (25s, 30s, 60s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8120003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: May be administered with or without dilution in NS; use of a nebulizer with a mouth piece, rather than a face mask, may be preferred to prevent contact with eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral Inhalation: Shake well before use (Atrovent&reg; only; Atrovent&reg; HFA does not require shaking); use spacer device in children &lt;8 years",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8120060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compatible for 1 hour when mixed with albuterol in a nebulizer.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10501672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; compatible for 1 hour when mixed with albuterol or metaproterenol in a nebulizer",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10501668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic bronchodilator used in bronchospasm associated with asthma, COPD, bronchitis, and emphysema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8117604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Atrovent&reg; may be confused with Alupent, Serevent&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ipratropium may be confused with tiotropium",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8120050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, nausea, taste perversion, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, COPD exacerbation, cough, dyspnea, rhinitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Accommodation disorder, anaphylactic reaction, angioedema, bronchospasm, corneal edema, eye pain (acute), glaucoma, hypersensitivity reactions, hypotension, intraocular pressure increased, laryngospasm, palpitations, stomatitis, tachycardia, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10501669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ipratropium, atropine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10501671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with narrow-angle glaucoma, bladder neck obstruction, or prostatic hypertrophy. Ipratropium is poorly absorbed from the lung; systemic effects are rare.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10501670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for first-line therapy; should be added to short-acting beta-agonists (SABA) therapy for severe exacerbations (NIH Guidelines, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8120053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: Ipratropium (Oral Inhalation) may enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8120042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8120043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Inhaled ipratropium is recommended for use as additional therapy for pregnant women with severe asthma exacerbations.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10501673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10501674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of bronchodilation: 1-3 minutes after administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Maximal effect within 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Bronchodilation persists for up to 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10501675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Not readily absorbed into the systemic circulation from the surface of the lung or from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Following inhalation, 15% of dose reaches the lower airways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10501676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/51/39732?source=see_link\">",
"      see \"Ipratropium (oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; avoid spraying aerosol in eyes as this may cause blurred vision or eye pain or discomfort and may precipitate or worsen glaucoma in susceptible patients",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10503584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atrovent&reg; HFA does not contain soya lecithin or any soy ingredients like the previous formulation did.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"Guidelines for the Diagnosis and Management of Asthma. NAEPP Expert Panel Report 3,\" August 2007. Available at:",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henry RI, Hiller EG, Milner AD, et al, &ldquo;Nebulized Ipratropium Bromide and Sodium Cromoglycate in the First 2 Years of Life,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1984, 59(1):54-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/59/4021/abstract-text/6230059/pubmed\" id=\"6230059\" target=\"_blank\">",
"        6230059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mann NP and Hiller RG, &ldquo;Ipratropium Bromide in Children With Asthma,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 1982, 37(1):72-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/59/4021/abstract-text/6461943/pubmed\" id=\"6461943\" target=\"_blank\">",
"        6461943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program, \"National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics &minus; 2002,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2002, 110(5 Suppl):S141-219.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/59/4021/abstract-text/12542074/pubmed\" id=\"12542074\" target=\"_blank\">",
"        12542074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh S, Johnson DW, Callahan S, et al, \"Efficacy of Frequent Nebulized Ipratropium Bromide Added to Frequent High-Dose Albuterol Therapy in Severe Childhood Asthma,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(4):639-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/59/4021/abstract-text/7699549/pubmed\" id=\"7699549\" target=\"_blank\">",
"        7699549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh S, Johnson DW, Canny G, et al, &ldquo;Efficacy of Adding Nebulized Ipratropium Bromide to Nebulized Albuterol Therapy in Acute Bronchiolitis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(6):920-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/59/4021/abstract-text/1437435/pubmed\" id=\"1437435\" target=\"_blank\">",
"        1437435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang EE, Milner R, Allen U, et al, \"Bronchodilators for Treatment of Mild Bronchiolitis: A Factorial Randomised Trial,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1992, 67(3):289-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/59/4021/abstract-text/1533504/pubmed\" id=\"1533504\" target=\"_blank\">",
"        1533504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilkie RA and Bryan MH, &ldquo;Effect of Bronchodilators on Airway Resistance in Ventilator-Dependent Neonates With Chronic Lung Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1987, 111(2):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/59/4021/abstract-text/2956405/pubmed\" id=\"2956405\" target=\"_blank\">",
"        2956405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16003 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4021=[""].join("\n");
var outline_f3_59_4021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120000\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120001\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501623\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443751\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503568\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120136\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120003\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503569\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120060\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501672\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501668\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8117604\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120050\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501669\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501671\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501670\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299541\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120053\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120042\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120043\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501673\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501674\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501675\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501676\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503584\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16003|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/7/21620?source=related_link\">",
"      Ipratropium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/62/13284?source=related_link\">",
"      Ipratropium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19155?source=related_link\">",
"      Ipratropium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36469?source=related_link\">",
"      Ipratropium (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/51/39732?source=related_link\">",
"      Ipratropium (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_59_4022="Saxagliptin and metformin: Patient drug information";
var content_f3_59_4022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Saxagliptin and metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40822?source=see_link\">",
"     see \"Saxagliptin and metformin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10967453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kombiglyze&trade; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11398844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11398845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11398792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3000777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to saxagliptin, metformin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, very bad kidney disease, or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11398794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11399308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11398796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11398847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694866",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11398793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11399309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11398797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16091 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-110.137.129.113-A26FC2219A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4022=[""].join("\n");
var outline_f3_59_4022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10967453\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398844\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398845\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398792\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398794\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11399308\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398796\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398847\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398793\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11399309\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11398797\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40822?source=related_link\">",
"      Saxagliptin and metformin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_59_4023="Midface anatomy";
var content_f3_59_4023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Midfacial anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ochs MW. Bony Oral-Maxillofacial Injuries. In: The Trauma Manual: Trauma and Acute Care Surgery, 3rd edition, Peitzman AB, Rhodes M, Schwab CW, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4023=[""].join("\n");
var outline_f3_59_4023=null;
var title_f3_59_4024="Developing vesicouterine fold";
var content_f3_59_4024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Developing the vesicouterine fold during hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4024=[""].join("\n");
var outline_f3_59_4024=null;
var title_f3_59_4025="Diagnosis and treatment of pericardial effusion";
var content_f3_59_4025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of pericardial effusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/59/4025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/59/4025/contributors\">",
"     Brian D Hoit, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/59/4025/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/59/4025/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/59/4025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/59/4025/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/59/4025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pericardium is a fibroelastic sac surrounding the heart that contains a thin layer of fluid. When the amount of pericardial fluid exceeds the small amount that is physiologic, a pericardial effusion results. Pericardial effusion can develop in patients with virtually any condition that affects the pericardium, including acute pericarditis and a variety of systemic disorders. The development of a pericardial effusion may have important implications for prognosis (as in patients with intrathoracic neoplasm), diagnosis (as in myopericarditis or acute pericarditis), or both (as in dissection of the ascending aorta).",
"   </p>",
"   <p>",
"    Pericardial effusions may develop rapidly (acute) or more gradually (subacute or chronic). The normal pericardium can stretch to accommodate increases in pericardial volume, with the amount of stretch related to how quickly the effusion develops (eg, the ability to stretch more with slowly developing effusions). However, regardless of how quickly an effusion develops, intrapericardial pressure from the accumulating fluid increases once the pericardium has been stretched to its limit. With ongoing accumulation of pericardial fluid into a closed space, the intrapericardial pressure begins to increase. When the intrapericardial pressure becomes high enough to impede cardiac filling, cardiac function becomes impaired and cardiac tamponade can be considered to be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general overview of the diagnosis and treatment of pericardial effusion will be presented here. The full spectrum of causes of pericardial disease, management of specific causes of pericardial disease, and the details of pericardial fluid drainage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial effusions can occur as a component of almost any pericardial disorder (",
"    <a class=\"graphic graphic_table graphicRef67851 \" href=\"UTD.htm?7/0/7181\">",
"     table 1",
"    </a>",
"    ), but the majority result from one of the following conditions (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute pericarditis (viral, bacterial, tuberculous, or idiopathic in origin)",
"     </li>",
"     <li>",
"      Autoimmune disease",
"     </li>",
"     <li>",
"      Postmyocardial infarction or cardiac surgery",
"     </li>",
"     <li>",
"      Sharp or blunt chest trauma, including a cardiac diagnostic or interventional procedure",
"     </li>",
"     <li>",
"      Malignancy, particularly metastatic spread of noncardiac primary tumors",
"     </li>",
"     <li>",
"      Mediastinal radiation",
"     </li>",
"     <li>",
"      Renal failure with uremia",
"     </li>",
"     <li>",
"      Hypothyroidism, especially myxedema",
"     </li>",
"     <li>",
"      Aortic dissection extending into the pericardium",
"     </li>",
"     <li>",
"      Selected drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of the different causes of pericardial effusion varies in published reports, depending primarily upon geography and the patient population (",
"    <a class=\"graphic graphic_table graphicRef78847 \" href=\"UTD.htm?33/52/34636\">",
"     table 2",
"    </a>",
"    ). Patients with hemorrhagic pericardial effusions have a somewhat different distribution of causes, although the overlap with serous effusions is significant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology of pericardial disease\", section on 'Spectrum of clinical presentation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Establish the cause of the effusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of pericardial effusion may be suspected from the history, physical examination, electrocardiogram (ECG), and chest x-ray. Unless cardiac tamponade is present, physical signs are so insensitive and nonspecific that they are of historic rather than practical interest. As an example, the ability to percuss cardiac dullness beyond the apical point of maximal impulse is consistent with pericardial effusion, but depends upon the absence of disease of the lower lobe of the left lung or left pleura and the expertise of the examiner. Ewart's sign (dullness at the left infrascapular area due to bronchial compression by a large effusion) suffers from similar limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients without a hemodynamically significant pericardial effusion will have no symptoms specific to the effusion, but may have symptoms related to the underlying cause (eg, fever in the setting of pericarditis, etc). Thus, pericardial effusions are often discovered incidentally during evaluation of other cardiopulmonary diseases. However, patients with a hemodynamically significant pericardial effusion leading to cardiac tamponade will usually present with signs and symptoms related to impaired cardiac function (ie, fatigue, dyspnea, elevated jugular venous pressure, edema). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial effusion should be suspected in the following clinical settings, particularly in patients with any of the disorders known to involve the pericardium (",
"    <a class=\"graphic graphic_table graphicRef67851 \" href=\"UTD.htm?7/0/7181\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All cases of acute pericarditis.",
"     </li>",
"     <li>",
"      Unexplained new radiographic cardiomegaly without pulmonary congestion.",
"     </li>",
"     <li>",
"      Unexplained persistent fever with or without an obvious source of infection, which raises the possibility of purulent pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=see_link\">",
"       \"Purulent pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Presence of isolated left (or left larger than right) pleural effusion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fever or hemodynamic deterioration in a patient with another disease process that can involve the pericardium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a pericardial effusion is suspected, the diagnostic approach consists of three steps: confirming the presence of a pericardial effusion; assessing the hemodynamic impact, if any, of the pericardial effusion; and, whenever possible, establishing the cause of the pericardial effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Establish the presence of effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation and ECG findings may suggest the presence of a pericardial effusion, but imaging, usually echocardiography, is required to establish the diagnosis. We perform echocardiography in all patients with suspected pericardial disease (",
"    <a class=\"graphic graphic_movie graphicRef76287 \" href=\"UTD.htm?10/29/10708\">",
"     movie 1",
"    </a>",
"    ). This practice is consistent with the 2003 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Society of Echocardiography",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ASE)",
"    </span>",
"    guidelines for the clinical application of echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography &ndash; Echocardiography is both specific and sensitive for the detection of pericardial effusion and can also provide information regarding the hemodynamic significance of the effusion. Pericardial fluid appears on an echocardiogram as an echolucent space between the pericardium and the epicardium. Small collections of pericardial fluid, which can be physiologic (25 to 50 mL), may be visible during ventricular systole. Effusions exceeding 25 to 50 mL are seen as an echo-free space throughout the cardiac cycle. Typically, a small free-flowing pericardial effusion is seen posterior to the left ventricle; this space diminishes and finally disappears as the echo beam approaches the base of the left ventricle and the left atrium (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61763 \" href=\"UTD.htm?3/35/3632\">",
"       image 1",
"      </a>",
"      ). Accumulation of pericardial fluid above the right atrium in the apical four chamber view with the patient in the left lateral decubitus position is, perhaps, the single most sensitive and specific indication of a pericardial effusion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82562 \" href=\"UTD.htm?9/48/9984\">",
"       image 2",
"      </a>",
"      ). However, in the case of a free flowing effusion, the site of accumulation may be positional as there is gravity dependence. As the effusion increases in size, it is typically seen anterior to the right ventricle. (See",
"      <a class=\"local\" href=\"#H23112237\">",
"       'Quantification of the pericardial effusion'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Although M mode echocardiography can identify an effusion (",
"      <a class=\"graphic graphic_figure graphicRef61898 \" href=\"UTD.htm?30/0/30725\">",
"       figure 1",
"      </a>",
"      ), two dimensional echocardiography permits a better estimate of the size of the effusion, its distribution, and its distance from potential puncture sites (",
"      <a class=\"graphic graphic_movie graphicRef76287 \" href=\"UTD.htm?10/29/10708\">",
"       movie 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=see_link\">",
"       \"Echocardiographic evaluation of the pericardium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ECG &ndash; Electrocardiographic (ECG) findings suggestive of pericardial effusion are low QRS voltage and electrical alternans. Low voltage is usually defined as QRS complexes &le;5 mm (0.5 mV) in all of the limb leads. This may or may not be accompanied by low voltage in the precordial leads, defined as a total QRS amplitude of &le;10 mm in V1 to V6. It has been suggested that low QRS voltage may be a manifestation of cardiac tamponade and pericardial inflammation, rather than pericardial effusion alone. Although consistent with pericardial effusion, low QRS voltage can also be present in a number of other disorders (",
"      <a class=\"graphic graphic_table graphicRef80629 \" href=\"UTD.htm?32/46/33515\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link\">",
"       \"Electrocardiogram in pericarditis and pericardial effusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H20#H20\">",
"       \"Cardiac tamponade\", section on 'Electrocardiography'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Electrical alternans refers to a beat-to-beat shift in the QRS (and sometimes the P wave) axis, amplitude,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      morphology. This shift occurs in association with swinging of the heart, usually in a large pericardial effusion (",
"      <a class=\"graphic graphic_waveform graphicRef72525 \" href=\"UTD.htm?42/27/43450\">",
"       waveform 1",
"      </a>",
"      ). The pattern is usually most apparent in one or more of the precordial leads. Alternans of QRS complex alone is not specific for pericardial effusion, but alternans of both P waves and QRS complexes is pathognomonic.",
"     </li>",
"     <li>",
"      Cardiac biomarkers &ndash; Among patients with pericardial effusion, cardiac biomarkers (CK-MB, troponin) may be elevated in those with acute pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=see_link\">",
"       \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link&amp;anchor=H2298771#H2298771\">",
"       \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Cardiac biomarkers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23112237\">",
"    <span class=\"h2\">",
"     Quantification of the pericardial effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;While echocardiography is an excellent method for detection and estimation of the size of pericardial effusions, it cannot precisely quantitate effusions because it is usually difficult to visualize and measure the entire pericardial sac in any one sector scan plane. Magnetic resonance imaging and computed tomography have advantages for fluid quantification. However, if a quantitation is desirable, a reasonable echocardiographic approach is to grade effusions as small, medium, or large as determined by the size of the echo-free space surrounding the heart.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small effusions are only seen posteriorly, typically 5 mm or less in thickness, and only cause minimal separation between the epicardial (visceral) pericardium and the thicker parietal pericardial sac.",
"     </li>",
"     <li>",
"      Moderate effusions tend to be seen along the length of the posterior wall but not anteriorly; the echo-free space is 5 to 20 mm at its greatest width.",
"     </li>",
"     <li>",
"      Large effusions tend to be seen circumferentially (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56462 \" href=\"UTD.htm?6/6/6240\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57021 \" href=\"UTD.htm?21/18/21794\">",
"       image 4",
"      </a>",
"      ); the echo-free space is 20 mm or more at its greatest width.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though size is relevant, as mentioned earlier, the hemodynamic consequence of a pericardial effusion is also related to the rate of fluid accumulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assess hemodynamic impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it is determined that a pericardial effusion is present, the next step is to determine its hemodynamic significance. The potential hemodynamic impact of an effusion ranges from none to mild compromise to the most extreme manifestation, cardiac tamponade (which, when severe enough, causes shock and circulatory collapse). Cardiac tamponade occurs when the intrapericardial pressure due to the accumulating pericardial effusion is elevated enough to impair filling of the cardiac chambers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that determine the degree of hemodynamic compromise include the volume of pericardial fluid, the rate at which the effusion accumulates, and whether or not the pericardium is scarred or adherent. Localized pericardial adhesions or organization of the pericardial fluid can result in localized, and thus atypical, tamponade. Diffuse pericardial inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scarring with effusion can result in effusive constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H23#H23\">",
"     \"Constrictive pericarditis\", section on 'Effusive constrictive pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute versus subacute tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tamponade can occur acutely (eg, due to rupture of the heart or aorta, trauma, or as a complication of catheter or pacemaker procedures) or subacutely (eg, due to neoplasm, uremia, or idiopathic pericarditis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cardiac tamponade is by definition rapid in onset, may be associated with chest pain and dyspnea, and is life-threatening if not promptly treated. The jugular venous pressure is markedly elevated, while hypotension is common due to the decline in cardiac output. The heart sounds are often muted. In most acute cases, the effusion is relatively small because the pericardium cannot stretch rapidly.",
"     </li>",
"     <li>",
"      Subacute cardiac tamponade is a less dramatic process. Patients may be asymptomatic or complain of dyspnea, chest discomfort or fullness, fatigability, or other symptoms referable to increased filling pressures and limited cardiac output. Peripheral edema may be seen with more chronic tamponade. The physical examination in subacute tamponade may reveal hypotension with a narrow pulse pressure, reflecting the limited stroke volume. However, patients with preexisting hypertension may remain hypertensive due to the increased sympathetic activity that is usually present in tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diagnosis of tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tamponade is based upon clinical and imaging evidence. Almost all patients with tamponade have one or more of the following physical findings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H13#H13\">",
"     \"Cardiac tamponade\", section on 'Physical findings'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sinus tachycardia",
"     </li>",
"     <li>",
"      Elevated jugular venous pressure",
"     </li>",
"     <li>",
"      Pulsus paradoxus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiography plays an important role in the diagnosis of cardiac tamponade. The echocardiographic features of tamponade are discussed in detail separately, but include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H22#H22\">",
"     \"Cardiac tamponade\", section on 'Echocardiography'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Collapse of the right atrium at end-diastole and the right ventricle in early diastole (",
"      <a class=\"graphic graphic_movie graphicRef74765 \" href=\"UTD.htm?37/37/38483\">",
"       movie 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef64027 \" href=\"UTD.htm?29/24/30094\">",
"       movie 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Reciprocal changes in left and right ventricular volumes with respiration, which are important in the pathogenesis of pulsus paradoxus (",
"      <a class=\"graphic graphic_figure graphicRef75980 \" href=\"UTD.htm?27/29/28116\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=see_link\">",
"       \"Pulsus paradoxus in pericardial disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased respiratory variation of mitral and tricuspid valve inflow velocities.",
"     </li>",
"     <li>",
"      Dilation (plethora) of the inferior vena cava and less than a 50 percent reduction in its diameter during inspiration, reflecting systemic congestion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58804 \" href=\"UTD.htm?24/55/25457\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79134 \" href=\"UTD.htm?40/27/41392\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Establish the cause of the effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical data and examination of the pericardial fluid and pericardium can be used to establish the cause of the effusion. Frequently, the cause of a pericardial effusion is suspected by the clinical setting in which it occurs. Examples include patients with breast or lung cancer, a recent myocardial infarction, severe hypothyroidism, or end-stage renal disease. In other cases, the diagnosis may be less apparent. Confirming the precise etiology of the pericardial effusion, however, generally requires sampling of the effusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the pericardium for laboratory analysis. The frequency of different causes of pericardial effusion varies in published reports, depending in part upon geography and patient demographics, as well as the aggressiveness with which an underlying diagnosis is sought (",
"    <a class=\"graphic graphic_table graphicRef78847 \" href=\"UTD.htm?33/52/34636\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of establishing a specific cause appears to increase with larger effusions. In series of patients with acute pericarditis (including those with small or undetectable effusions), the underlying diagnosis was established in only about 15 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In contrast, studies evaluating moderate to large pericardial effusions have revealed diagnoses in up to 90 percent of cases when very aggressive diagnostic approaches are taken [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/7\">",
"     7",
"    </a>",
"    ]. Such aggressive approaches are often not warranted in clinical practice, however, given the benign natural history of many of these effusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link&amp;anchor=H2299910#H2299910\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Identifying the etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected clinical information may be helpful for establishing the etiology of a pericardial effusion. This was illustrated in a review of 322 patients with a moderate or large pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/6\">",
"     6",
"    </a>",
"    ]. In 60 percent of patients, the cause of the effusion was a known medical condition. In the remaining patients, the cause of the effusion was assessed based upon the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The size of the effusion",
"     </li>",
"     <li>",
"      The presence or absence of tamponade",
"     </li>",
"     <li>",
"      Inflammatory signs (defined as two or more of the following features: characteristic chest pain; pericardial friction rub; fever &gt;37&ordm;C; and diffuse ST segment elevation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence or absence of these features suggested, but did not confirm, a specific diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of inflammatory signs was associated with acute idiopathic pericarditis (likelihood ratio 5.4).",
"     </li>",
"     <li>",
"      A large effusion without inflammatory signs or tamponade was associated with chronic idiopathic pericardial effusion (likelihood ratio 20).",
"     </li>",
"     <li>",
"      Tamponade without inflammatory signs was associated with a malignant effusion (likelihood ratio 2.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the initial history and physical examination do not suggest a specific diagnosis, extensive laboratory testing seeking an etiology is unlikely to be helpful. In such cases, we limit routine testing to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Chemistry profile and renal function",
"     </li>",
"     <li>",
"      Thyroid function",
"     </li>",
"     <li>",
"      Anti-double stranded DNA, serum complement",
"     </li>",
"     <li>",
"      Chest radiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pericardial fluid analysis and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage of a pericardial effusion is often performed for therapeutic benefit (ie, in cardiac tamponade). However, pericardial fluid drainage and analysis should be considered for diagnostic purposes in patients without cardiac tamponade if there is significant uncertainty regarding the diagnosis or if knowledge of a particular diagnosis would change the management of the patient (ie, the presence of metastatic malignancy). In addition, pericardial biopsy can be an important part of the diagnostic approach.",
"   </p>",
"   <p>",
"    The invasive nature of pericardiocentesis and pericardial biopsy must be weighed against two factors: a relatively low diagnostic yield from the procedure, and the clinical relevance of a specific diagnosis, as many low-risk patients can be managed empirically without making a specific diagnosis. The yield of diagnostic pericardiocentesis has varied in different series, but in most, a definitive diagnosis has been made following pericardiocentesis in less than 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. When an etiology for the pericardial effusion was confirmed, malignancy, purulent infection, and tuberculosis were the most frequently identified causes.",
"   </p>",
"   <p>",
"    We consider pericardial fluid analysis and pericardial biopsy separately, since they are frequently helpful but many patients are successfully managed without either procedure. Our approach is in general agreement with the 2004 European Society of Cardiology guidelines for the diagnosis and management of pericardial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We perform pericardial fluid analysis in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In any patient undergoing therapeutic pericardiocentesis for treatment of cardiac tamponade (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Cardiac tamponade'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      When there is a clinical suspicion of purulent, tuberculous, or neoplastic pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=see_link\">",
"       \"Purulent pericarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"       \"Tuberculous pericarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link\">",
"       \"Pericardial disease associated with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with moderate-to-large pericardial effusions of unknown etiology that do not respond rapidly to anti-inflammatory therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with chronic pericardial effusions, we do not recommend repeated diagnostic pericardiocentesis due to its low yield.",
"   </p>",
"   <p>",
"    The biochemical, immunologic, cytologic, and bacteriologic characteristics of an effusion can be established by laboratory analysis of the pericardial fluid. In some cases this analysis can also determine the etiology of the effusion. Among the most helpful diagnostic studies are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Culture",
"     </li>",
"     <li>",
"      Cytology",
"     </li>",
"     <li>",
"      Adenosine deaminase, interferon-gamma, or lysozyme (for tuberculous pericarditis) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polymerase chain reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parameters such as protein, LDH, glucose, red cell count, and white cell count do not reliably distinguish exudative from transudative effusions and are rarely helpful in establishing an etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If patient characteristics and local expertise favor pericardial drainage via percutaneous pericardiocentesis, analysis is limited to the pericardial fluid. However, whenever surgical drainage is performed, we also recommend pericardial biopsy. In addition, pericardial biopsy should be performed in any patient in whom there is ongoing diagnostic uncertainty as to the etiology, if a specific diagnosis would significantly change the management.",
"   </p>",
"   <p>",
"    Pericardioscopy enables endoscopic inspection and targeted biopsy of the parietal and visceral pericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/1\">",
"     1",
"    </a>",
"    ]. This approach has been used in patients with unexplained pericardial effusions or to diagnose recurrent idiopathic effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. When performed in one of the few centers with a special interest and expertise in using this approach, a specific diagnosis was established in 49 to 65 percent of patients, a value higher than generally obtained by pericardial biopsy performed under fluoroscopic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several issues must be considered in the management of patients with a pericardial effusion, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of cardiac tamponade resulting from a hemodynamically significant effusion",
"     </li>",
"     <li>",
"      Diagnosis and treatment of the underlying disease",
"     </li>",
"     <li>",
"      Management of patients with a chronic large effusion or recurrent idiopathic effusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac tamponade can occur in any patient with a pericardial effusion, regardless of the cause. When cardiac tamponade is present, urgent management is indicated and primarily involves drainage of the effusion, although fluid resuscitation in hypovolemic patients may temporarily improve their hemodynamic status. The clinical features and management of cardiac tamponade are presented in detail separately and briefly below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Clinical assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Volume resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are initially hypovolemic, volume resuscitation may result in hemodynamic improvement, and such patients can then be observed closely without urgent pericardiocentesis. However, patients who are hemodynamically unstable despite achieving euvolemia are unlikely to stabilize with further volume resuscitation. In such cases, urgent pericardial drainage is necessary, and volume resuscitation should be considered only as a temporizing measure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pericardial fluid drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cardiac tamponade and evidence of hemodynamic compromise require urgent drainage of the pericardial effusion. The choice between pericardiocentesis and open surgical drainage is based upon local preference and experience, and upon individual patient considerations.",
"   </p>",
"   <p>",
"    Percutaneous catheter drainage, or pericardiocentesis, is the more common method in most hospitals for draining a pericardial effusion. This can be performed under fluoroscopic or echocardiographic guidance, and may be followed by continuous catheter drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In this approach, an indwelling catheter is placed in the pericardial space, with intermittent or continuous fluid removal until the rate of fluid return is negligible (&lt;25 mL over 24 hours), at which point the catheter is removed. An extensive discussion of pericardiocentesis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical pericardiectomy and drainage, though less commonly performed than pericardiocentesis, is often preferred in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pericardial effusion has reaccumulated after prior percutaneous drainage.",
"     </li>",
"     <li>",
"      The pericardial effusion is loculated.",
"     </li>",
"     <li>",
"      Biopsy of the pericardium is desired for diagnostic purposes.",
"     </li>",
"     <li>",
"      The patient has a coagulopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Percutaneous balloon pericardiotomy is an alternative approach that has primarily been used in patients with malignant effusions in whom the quality of remaining life is paramount [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link&amp;anchor=H23#H23\">",
"     \"Pericardial disease associated with malignancy\", section on 'Balloon pericardiotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2067265\">",
"    <span class=\"h2\">",
"     Underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a pericardial effusion who are hemodynamically stable with no evidence of cardiac tamponade, immediate drainage of the effusion is not required. Instead, diagnosis of the underlying cause of the effusion, with treatment aimed at the underlying condition rather than the effusion itself, may result in clinical improvement and resolution of the effusion without the need for percutaneous or surgical drainage.",
"   </p>",
"   <p>",
"    The management of specific underlying disease states associated with pericardial effusion, including acute pericarditis, uremia, and malignancy, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link\">",
"     \"Treatment of acute pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H6#H6\">",
"     \"Recurrent pericarditis\", section on 'Therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link&amp;anchor=H21#H21\">",
"     \"Tuberculous pericarditis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=see_link&amp;anchor=H18#H18\">",
"     \"Purulent pericarditis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6533?source=see_link&amp;anchor=H4#H4\">",
"     \"Pericarditis in renal failure\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link&amp;anchor=H17#H17\">",
"     \"Pericardial disease associated with malignancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic and recurrent effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial effusions may persist for extended periods and can also recur with repeated episodes of pericarditis. As in other cases of pericardial effusion, management in these settings is based upon the treatment of the underlying disorder, with percutaneous drainage of the effusion reserved for hemodynamically significant or persistently symptomatic effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pericardial effusions that are present for weeks to months, or longer, are referred to as chronic effusions or chronic effusive pericarditis. In such cases, the diagnostic work-up often fails to reveal the cause, although an etiology may emerge over time.",
"   </p>",
"   <p>",
"    The incidence and significance of chronic effusions were illustrated in a series of 1108 patients who initially presented with pericarditis, of whom a very small fraction (2.5 percent) had a large idiopathic effusion that persisted for a median duration of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/24\">",
"     24",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-six percent of patients with a large effusion were asymptomatic at the initial evaluation, while 29 percent presented with tamponade and another 29 percent developed tamponade during the course of follow-up.",
"     </li>",
"     <li>",
"      Among 86 percent of the patients with a large effusion who underwent therapeutic pericardiocentesis, a persistent marked reduction in, or disappearance of, the effusion occurred in 29 percent, early pericardiectomy was required in 18 percent, and a large pericardial effusion reappeared in 39 percent.",
"     </li>",
"     <li>",
"      Overall, 71 percent of patients presenting with large effusions underwent pericardiectomy because pericardiocentesis alone was inadequate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although chronic effusions are often asymptomatic and hemodynamically tolerated, tamponade can unexpectedly occur at any time.",
"   </p>",
"   <p>",
"    In patients with large chronic effusions, we perform pericardiocentesis initially because the effusion may not reaccumulate. If pericardiocentesis is undertaken, careful follow-up over days to weeks is essential because of the significant and unpredictable incidence of future tamponade. If the effusion reaccumulates, we perform repeated pericardiocentesis or pericardiectomy. The major indication for pericardiectomy is the reaccumulation of pericardial fluid despite repeated pericardiocenteses. For both chronic and recurrent effusions, the 2004 European Society of Cardiology guidelines for the management of pericardial disease suggested surgical pericardiectomy only in patients with symptomatic effusions in whom medical therapy and repeated pericardiocentesis were not successful [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4025/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Pericardial fluid drainage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34577?source=see_link\">",
"       \"Patient information: Cardiac tamponade (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardial effusion can develop in patients with virtually any condition that affects the pericardium (",
"      <a class=\"graphic graphic_table graphicRef67851 \" href=\"UTD.htm?7/0/7181\">",
"       table 1",
"      </a>",
"      ), including acute pericarditis and a variety of systemic disorders. The frequency of different causes of pericardial effusion varies in published reports, depending in part upon geography and patient demographics, as well as the aggressiveness with which an underlying diagnosis is sought (",
"      <a class=\"graphic graphic_table graphicRef78847 \" href=\"UTD.htm?33/52/34636\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of pericardial effusion may be suspected from the history, physical examination, electrocardiogram (ECG), and chest x-ray. However, in the absence of cardiac tamponade, physical signs are not sensitive or specific for pericardial effusion. Therefore, the diagnosis in most patients is confirmed using echocardiography. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach to the patient with a suspected pericardial effusion consists of the following steps:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Establish the presence of an effusion &ndash; This is usually done with echocardiography. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Establish the presence of effusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assess the hemodynamic impact of the effusion &ndash; Both clinical and echocardiographic findings can be helpful in assessing the hemodynamic impact of a pericardial effusion. The most important issue is the assessment for cardiac tamponade, which occurs when the intrapericardial pressure from an accumulating pericardial effusion impedes filling of one or usually both ventricles. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Assess hemodynamic impact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Establish the cause of the effusion &ndash; In some cases, the most likely cause of the pericardial effusion will be clear due to the presence of another illness or systemic disorder known to involve the pericardium. If the cause is not apparent, the routine use of a broad panel of screening laboratory tests is not usually helpful. In such cases, evaluation of the pericardial fluid and pericardium itself may suggest an etiology, particularly if the effusion is large. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Establish the cause of the effusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of a pericardial effusion involves the management of the hemodynamic consequences (ie, cardiac tamponade) of the effusion, treatment of the underlying disease, and management of large asymptomatic effusions or recurrent effusions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"       \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with a documented pericardial effusion and clinical evidence of hemodynamic compromise (ie, tachycardia and hypotension producing a picture of cardiogenic shock) consistent with cardiac tamponade, urgent drainage of the pericardial effusion should be performed. Drainage of the effusion can be performed percutaneously using catheter drainage or surgically. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pericardial fluid drainage'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Volume resuscitation, which may lead to some improvement in hemodynamic status, is usually a temporizing measure during preparation for a drainage procedure. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Volume resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of hemodynamically stable pericardial effusions should focus on treatment of the underlying condition rather than the effusion itself. This may result in clinical improvement and resolution of the effusion without the need for percutaneous or surgical drainage. Treatment of the illnesses associated with pericardial effusions is discussed separately. (See",
"      <a class=\"local\" href=\"#H2067265\">",
"       'Underlying disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardial effusions that are present for three months or more are referred to as chronic effusions or chronic effusive pericarditis. In patients with large chronic effusions, we perform pericardiocentesis initially because the effusion may not reaccumulate. If pericardiocentesis is undertaken, careful follow-up over days to weeks is essential because of the significant and unpredictable incidence of future tamponade. If the effusion reaccumulates, we perform repeated pericardiocentesis or pericardiectomy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chronic and recurrent effusions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477866456\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. G. Ralph Corey, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/1\">",
"      Ewart W. Practical Aids in the Diagnosis of Pericardial Effusion, in Connection with the Question as to Surgical Treatment. Br Med J 1896; 1:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/2\">",
"      Weiss JM, Spodick DH. Association of left pleural effusion with pericardial disease. N Engl J Med 1983; 308:696.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/4\">",
"      Shabetai R. Pericardial effusion: haemodynamic spectrum. Heart 2004; 90:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/5\">",
"      Brown J, MacKinnon D, King A, Vanderbush E. Elevated arterial blood pressure in cardiac tamponade. N Engl J Med 1992; 327:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/6\">",
"      Sagrist&agrave;-Sauleda J, Merc&eacute; J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the causes of large pericardial effusions. Am J Med 2000; 109:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/7\">",
"      Corey GR, Campbell PT, Van Trigt P, et al. Etiology of large pericardial effusions. Am J Med 1993; 95:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/8\">",
"      Levy PY, Corey R, Berger P, et al. Etiologic diagnosis of 204 pericardial effusions. Medicine (Baltimore) 2003; 82:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/9\">",
"      Permanyer-Miralda G, Sagrist&aacute;-Sauleda J, Soler-Soler J. Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol 1985; 56:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/10\">",
"      Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol 1995; 75:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/11\">",
"      Maisch B, Seferovi�� PM, Risti�� AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/12\">",
"      Tuon FF, Litvoc MN, Lopes MI. Adenosine deaminase and tuberculous pericarditis--a systematic review with meta-analysis. Acta Trop 2006; 99:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/13\">",
"      Levy PY, Fournier PE, Charrel R, et al. Molecular analysis of pericardial fluid: a 7-year experience. Eur Heart J 2006; 27:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/14\">",
"      Ben-Horin S, Bank I, Shinfeld A, et al. Diagnostic value of the biochemical composition of pericardial effusions in patients undergoing pericardiocentesis. Am J Cardiol 2007; 99:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/15\">",
"      Nugue O, Millaire A, Porte H, et al. Pericardioscopy in the etiologic diagnosis of pericardial effusion in 141 consecutive patients. Circulation 1996; 94:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/16\">",
"      Pankuweit S, W&auml;dlich A, Meyer E, et al. Cytokine activation in pericardial fluids in different forms of pericarditis. Herz 2000; 25:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/17\">",
"      Seferovi�� PM, Risti�� AD, Maksimovi�� R, et al. Diagnostic value of pericardial biopsy: improvement with extensive sampling enabled by pericardioscopy. Circulation 2003; 107:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/18\">",
"      Maisch B, Risti�� AD, Pankuweit S. Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 2002; 23:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/19\">",
"      Kopecky SL, Callahan JA, Tajik AJ, Seward JB. Percutaneous pericardial catheter drainage: report of 42 consecutive cases. Am J Cardiol 1986; 58:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/20\">",
"      Tsang TS, Barnes ME, Gersh BJ, et al. Outcomes of clinically significant idiopathic pericardial effusion requiring intervention. Am J Cardiol 2003; 91:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/21\">",
"      Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002; 77:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/22\">",
"      Ziskind AA, Pearce AC, Lemmon CC, et al. Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. J Am Coll Cardiol 1993; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/23\">",
"      Merc&eacute; J, Sagrist&agrave;-Sauleda J, Permanyer-Miralda G, Soler-Soler J. Should pericardial drainage be performed routinely in patients who have a large pericardial effusion without tamponade? Am J Med 1998; 105:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4025/abstract/24\">",
"      Sagrist&agrave;-Sauleda J, Angel J, Permanyer-Miralda G, Soler-Soler J. Long-term follow-up of idiopathic chronic pericardial effusion. N Engl J Med 1999; 341:2054.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4941 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4025=[""].join("\n");
var outline_f3_59_4025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Establish the presence of effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23112237\">",
"      Quantification of the pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assess hemodynamic impact",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute versus subacute tamponade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diagnosis of tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Establish the cause of the effusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pericardial fluid analysis and biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Volume resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pericardial fluid drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2067265\">",
"      Underlying disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic and recurrent effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477866456\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4941|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/35/3632\" title=\"diagnostic image 1\">",
"      Small pericardial effusion II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/48/9984\" title=\"diagnostic image 2\">",
"      Small pericardial effusion I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/6/6240\" title=\"diagnostic image 3\">",
"      Large pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/18/21794\" title=\"diagnostic image 4\">",
"      4 chamber view showing circumferential pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/55/25457\" title=\"diagnostic image 5\">",
"      2D TTE Subcostal view normal IVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/27/41392\" title=\"diagnostic image 6\">",
"      Subcostal view IVC during cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4941|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/0/30725\" title=\"figure 1\">",
"      M mode echo parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/29/28116\" title=\"figure 2\">",
"      Hemodynamics tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4941|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/29/10708\" title=\"movie 1\">",
"      Pericardial effusion parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?37/37/38483\" title=\"movie 2\">",
"      Pericardial effusion with tamponade subcostal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/24/30094\" title=\"movie 3\">",
"      Pericardial effusion with tamponade subcostal view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/0/7181\" title=\"table 1\">",
"      Causes of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/52/34636\" title=\"table 2\">",
"      Causes of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33515\" title=\"table 3\">",
"      Causes of low QRS voltage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4941|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/27/43450\" title=\"waveform 1\">",
"      ECG in electrical alternans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=related_link\">",
"      Echocardiographic evaluation of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34577?source=related_link\">",
"      Patient information: Cardiac tamponade (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6533?source=related_link\">",
"      Pericarditis in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=related_link\">",
"      Pulsus paradoxus in pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=related_link\">",
"      Purulent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=related_link\">",
"      Treatment of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=related_link\">",
"      Tuberculous pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_59_4026="Lacunar infarcts";
var content_f3_59_4026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lacunar infarcts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/59/4026/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/59/4026/contributors\">",
"     Jamary Oliveira-Filho, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/59/4026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/59/4026/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/59/4026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/59/4026/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/59/4026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacunar infarcts are small (0.2 to 15 mm in diameter) noncortical infarcts caused by occlusion of a single penetrating branch of a large cerebral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/1\">",
"     1",
"    </a>",
"    ]. These branches arise at acute angles from the large arteries of the circle of Willis, stem of the middle cerebral artery (MCA), or the basilar artery. Although this definition implies that pathological confirmation is necessary, diagnosis in vivo may be made in the setting of appropriate clinical syndromes and radiological tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dechambre first used the term \"lacune\" in 1838 to describe softenings in subcortical regions of the brain found on autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/2\">",
"     2",
"    </a>",
"    ]. At the time, there was dispute regarding whether these lacunes were caused by encephalitis, a late phase of a small hemorrhage, or ischemic necrosis. Marie in 1901 first described a clinical syndrome associated with multiple lacunes, characterized by sudden hemiplegia with good recovery, a characteristic gait with small steps (\"marche a petits pas de Dejerine\"), pseudobulbar palsy, and dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 1960s, careful clinicopathological correlations by Fisher generated the so-called \"lacunar hypothesis,\" which suggested that lacunes are due to a chronic vasculopathy related to systemic hypertension, cause a variety of defined clinical syndromes, and imply a generally good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The introduction of CT and MRI has generated data that both supports and opposes the lacunar theory [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Some authors have suggested abandoning the concept altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Detractors of the lacunar hypothesis note the lack of animal data or an animal model of lacunar infarction and the demonstration of embolic sources from the heart, aorta, or large arteries in a substantial percentage of lacunar strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Proponents concede that some small number of lacunes may result from emboli, but they point out that the proportion of embolic sources found in association with lacunar syndromes is far lower than for other ischemic stroke types and that there are clear clinical and epidemiologic reasons to separate lacunes from other ischemic stroke subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the major difficulties in interpreting these data stems from the inability of imaging techniques to show that an infarct was due to occlusion of a single penetrating artery. Furthermore, various studies have used different sets of criteria to define \"lacunar infarcts\" and the many lacunar syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, continuing publications on the subject have demonstrated that the term \"lacune\" is clinically useful and has gained wide acceptance in the literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VASCULAR ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most lacunes occur in the basal ganglia (putamen, globus pallidus, thalamus, caudate), subcortical white matter (internal capsule and corona radiata), and pons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/4,14,15\">",
"     4,14,15",
"    </a>",
"    ]. These locations correspond to vascular territories of the lenticulostriate branches from the anterior and middle cerebral arteries, the recurrent artery of Heubner from the anterior cerebral artery, the anterior choroidal artery from the distal internal carotid artery, thalamoperforant branches from the posterior cerebral artery, and paramedian branches from the basilar artery (",
"    <a class=\"graphic graphic_figure graphicRef73027 \" href=\"UTD.htm?41/6/42086\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These small branches originate directly from large arteries, making them particularly vulnerable to the effects of hypertension, probably explaining this peculiar distribution.",
"   </p>",
"   <p>",
"    A study using fluorescent and radiopaque dye injection techniques has demonstrated that penetrating vessels supply distinct microvascular territories of the basal ganglia, with minimal overlap and sparse anastomoses between the penetrating vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/17\">",
"     17",
"    </a>",
"    ]. The ultimately terminal rather than anastomotic nature of these vessels is another factor explaining the predisposition of this region to lacunar infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanisms for occlusion of small penetrator branches have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipohyalinosis of the penetrating arteries is the usual cause, particularly of smaller infarcts (3 to 7 mm in length).",
"     </li>",
"     <li>",
"      Microatheroma of the origin of the penetrating arteries coming off the middle cerebral artery stem, circle of Willis, or distal basilar or vertebral arteries. This mechanism has been proven pathologically by serial section for the basilar artery.",
"     </li>",
"     <li>",
"      In some cases, not proven pathologically, tiny emboli have been suspected as the cause of these small infarcts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two mechanisms are proven pathologically [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/1\">",
"     1",
"    </a>",
"    ], and generally regarded as a consequence of systemic hypertension. The third mechanism is supported both experimentally [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/19\">",
"     19",
"    </a>",
"    ] and by case reports of lacunes in patients with high-risk cardiac sources for emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/20\">",
"     20",
"    </a>",
"    ] or following cardiac and arch angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study, lacunar infarcts in the territory of a single perforating branch artery of the middle cerebral artery (MCA) were found significantly more often in association with atherosclerotic MCA occlusive disease than with internal carotid occlusive disease or cardiac embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/22\">",
"     22",
"    </a>",
"    ]. This observation supports the hypothesis that some lacunar strokes are caused by parent artery (eg, MCA or basilar artery) atheroma that occludes the origin of the penetrating artery.",
"   </p>",
"   <p>",
"    Other mechanisms have been proposed to account for lacunar infarcts, but none are pathologically proven. One alternate explanation to the lacunar hypothesis is that failure of the arteriolar endothelium and the blood-brain barrier leads to lacunar stroke and white matter lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. This failure allows extravasation of blood components into the vessel wall, which results in damage to the vessel wall, perivascular neurons, and glia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, one neuropathologic study found no compelling evidence of a specific cerebral endothelial response in patients with small vessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathology of lacunar infarcts may be changing as the medical management of hypertension becomes more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/29\">",
"     29",
"    </a>",
"    ]. A decline in the number of lacunes per patient in comparable pathology series has been attributed to the introduction of antihypertensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/1\">",
"     1",
"    </a>",
"    ]. Another neuropathology study in lacunar infarcts found only 69 percent of patients with evidence of systemic hypertension and rare cases of classic lipohyalinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/29\">",
"     29",
"    </a>",
"    ], further suggesting that modern antihypertensive therapy may have changed the natural history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pathophysiology of lacunes.",
"   </p>",
"   <p>",
"    Of interest regarding mechanism, a systematic review of 19 cohort studies involving 5864 patients with ischemic stroke found that those who had a lacunar infarct as the index event were more likely to have lacunar than nonlacunar stroke recurrence, lending some support to the notion that lacunar strokes represent a different form of arteriopathy than other ischemic stroke subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies investigating possible stroke mechanisms in lacunar infarcts have found carotid stenosis in 13 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and cardiac sources in 18 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] of patients with a radiologically-demonstrated lacunes. These rates are much lower than those of patients with cortical infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31,34\">",
"     31,34",
"    </a>",
"    ] and may be similar to asymptomatic elderly populations, making the argument of a causal relationship between the verified sources and the lacunes difficult to prove. It also appears that patients with lacunar infarcts more often have milder degrees of carotid stenosis than those with cortical infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/35\">",
"     35",
"    </a>",
"    ]. On the other hand, ipsilateral carotid stenosis appears to be more common than contralateral stenosis, which supports a possible causal relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some reports, multiple acute to subacute subcortical or small cortical infarcts have been detected by diffusion-weighted magnetic resonance imaging (DWI), suggesting an embolic source.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study using DWI in patients presenting with a lacunar syndrome found that 16 percent had multiple infarcts detected as DWI-hyperintense lesions, implying that all lesions were acute to subacute (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54402 \" href=\"UTD.htm?17/38/18023\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/37\">",
"       37",
"      </a>",
"      ]. This subgroup more frequently harbored a proximal embolic source than patients with single lesions (p &lt;0.05).",
"     </li>",
"     <li>",
"      Another case series evaluated 73 patients presenting with lacunar syndromes; all underwent DWI as well as extensive neurovascular and cardiac evaluations for potential embolic sources [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/38\">",
"       38",
"      </a>",
"      ]. DWI radiologic patterns suggestive of nonlacunar infarction (mainly embolism) were seen in a total of 30 patients (41 percent); of these, 16 had one large or multiple acute lesions within a single vascular territory, and another 14 had multiple infarcts in different vascular territories [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/38\">",
"       38",
"      </a>",
"      ]. Patients with more than one infarct on DWI were significantly more likely to have a clinically proven embolic source, although no embolic source was found in nine patients with a DWI pattern suggestive of a",
"      <span class=\"nowrap\">",
"       nonlacunar/embolic",
"      </span>",
"      stroke mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence rate of lacunar infarcts depends upon the population studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study from Italy, the incidence rate of lacunar infarct standardized to the 1996 European population was 26.3 per 100,000 population [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/39\">",
"       39",
"      </a>",
"      ]. Lacunes accounted for 15 percent of first-ever ischemic strokes.",
"     </li>",
"     <li>",
"      Among a community-based population of predominantly white residents of Rochester, Minnesota, the incidence rate of lacunar infarct between 1985 and 1989 was 29 per 100,000 population [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/40\">",
"       40",
"      </a>",
"      ]. Lacunes accounted for 16 percent of first-ever ischemic strokes.",
"     </li>",
"     <li>",
"      Among a community-based population of black residents of a metropolitan area of Cincinnati, Ohio, the incidence rate of lacunar infarct was 52 per 100,000 population [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/41\">",
"       41",
"      </a>",
"      ]. Lacunes accounted for 22 percent of first-ever ischemic strokes.",
"     </li>",
"     <li>",
"      Among populations of patients in referral based studies, lacunes account for a larger proportion of ischemic strokes, 26 percent in the Stroke Data Bank [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One group estimated that 18 percent of first ischemic strokes in the United States are lacunes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/40\">",
"     40",
"    </a>",
"    ]. This compares with 16 percent due to large vessel atherosclerosis with stenosis, 26 percent cardioembolic, 3 percent due to an uncommon mechanism, and 37 percent of unknown or no obvious cause.",
"   </p>",
"   <p>",
"    A population-based study from Japan suggests that the incidence of lacunar stroke has been steadily declining since the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/42\">",
"     42",
"    </a>",
"    ]. This finding was attributed to improved control of hypertension and decreased prevalence of smoking during the last 40 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, two of the three described mechanisms for lacunar stroke are related to a chronic vasculopathy associated with systemic hypertension. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other likely risk factors for lacunar infarction include diabetes mellitus and possibly smoking, age, and low-density lipoprotein (LDL) cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/43\">",
"     43",
"    </a>",
"    ]. Hyperhomocysteinemia has been associated with an increased risk of ischemic stroke and lacunar infarction in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypertension and diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension and diabetes mellitus are associated with an increased risk of stroke in general. Whether they are more commonly associated with lacunar stroke and small vessel disease compared with other stroke subtypes (as many believe) is not clear, since the evidence is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. The answer may depend upon the population studied and the criteria used to define lacunar-type infarction.",
"   </p>",
"   <p>",
"    One explanation for the difference in lacunar stroke incidence rates between whites and blacks cited above (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Epidemiology'",
"    </a>",
"    above) is a higher incidence of risk factors such as diabetes and hypertension among blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/41\">",
"     41",
"    </a>",
"    ]. In the community-based study of blacks in Cincinnati, Ohio, the odds ratios of first-ever lacunar infarct among patients with diabetes or hypertension were 4.4 and 5.0, respectively, compared with nondiabetic and normotensive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/41\">",
"     41",
"    </a>",
"    ]. The attributable risk (proportion of cases that can be attributed to the risk factor) for these two diseases were 30 and 68 percent, respectively (hypertension has a greater impact than diabetes because of its higher overall prevalence in the population). The rates of hypertension and current smoking were found to be significantly increased in patients with lacunar infarcts compared with other stroke subtypes.",
"   </p>",
"   <p>",
"    Other studies have also found a difference in the incidence of risk factors between patients with lacunar stroke and those with other stroke subtypes. In the Stroke Data Bank, patients with lacunar stroke had fewer previous transient ischemic attacks (TIAs) and strokes than those with large vessel atherosclerotic infarction and, compared with patients who had cardioembolic strokes, those with lacunar infarcts more frequently had hypertension and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings contrast with some other community-based studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/40,50\">",
"     40,50",
"    </a>",
"    ]. As an example, in the Oxfordshire Community Stroke Project, a study of first-ever stroke, comparison between the risk factor profiles of patients with lacunar infarction and carotid artery distribution infarct involving the cortex found that the two groups did not differ in the prevalence of prestroke hypertension or markers of sustained hypertension, or in the prevalence of other risk factors for ischemic stroke such as diabetes mellitus, previous TIA, cervical bruit, peripheral vascular disease, or cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/50\">",
"     50",
"    </a>",
"    ]. Similarly, the Rochester, Minnesota study found no greater incidence of diabetes and hypertension among patients with lacunar infarcts and those with other stroke subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The APOE e4 allele may confer some risk of developing small vessel pathology, as there is evidence that amyloid beta peptide levels are associated with an increased risk for lacunar stroke in carriers of the APOE e4 allele [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/51\">",
"     51",
"    </a>",
"    ] and that APOE e4 carriers are at increased risk for the development of subcortical white matter lesions, if they are also hypertensive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/52\">",
"     52",
"    </a>",
"    ]. These observations require further confirmation.",
"   </p>",
"   <p>",
"    Additional genetic factors that may play a role in the development of small vessel disease and lacunar stroke include homozygosity for the T allele located at position -7351 within the enhancer region of the tissue plasminogen activator (TPA) gene (the",
"    <span class=\"nowrap\">",
"     T/C",
"    </span>",
"    enhancer polymorphism) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/53\">",
"     53",
"    </a>",
"    ] and the D allele of the angiotensin converting enzyme (ACE)",
"    <span class=\"nowrap\">",
"     insertion/deletion",
"    </span>",
"    genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, several rare conditions are characterized by hereditary cerebral small vessel arteriopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=see_link\">",
"       \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Familial cerebral amyloid angiopathy, an important cause of primary lobar intracerebral hemorrhage in the elderly, characterized by the deposition of congophilic material in small to medium-sized blood vessels of the brain and leptomeninges (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"       \"Cerebral amyloid angiopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autosomal dominant retinal vasculopathy with cerebral leukodystrophy (also called cerebroretinal vasculopathy, hereditary vascular retinopathy, and hereditary endotheliopathy with retinopathy nephropathy and stroke [HERNS]) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/55-58\">",
"       55-58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Brain small vessel disease with hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/60-63\">",
"       60-63",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While all of these conditions affect small vessels and may theoretically manifest as a classic lacunar syndrome, CADASIL is most likely to do so. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=see_link&amp;anchor=H10#H10\">",
"     \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\", section on 'Ischemic stroke and TIA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute identification of lacunar syndromes is important in triaging medical resources, choosing among treatment modalities, and predicting clinical outcome. As a general rule, lacunar syndromes lack findings such as aphasia, agnosia, neglect, apraxia, or hemianopsia (so-called \"cortical\" signs). Monoplegia, stupor, coma, loss of consciousness, and seizures also are typically absent.",
"   </p>",
"   <p>",
"    Penetrating artery occlusions usually cause symptoms that develop over a short period of time, typically minutes to hours (",
"    <a class=\"graphic graphic_figure graphicRef52246 \" href=\"UTD.htm?24/54/25453\">",
"     figure 2",
"    </a>",
"    ). However, a stuttering course may ensue, as with large artery thrombosis, and symptoms sometimes evolve over several days. In fact, lacunar infarction is the main ischemic stroke subtype associated with worsening motor deficits after hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 20 lacunar syndromes have been described. Five have been validated as being highly predictive for the presence of lacunes radiologically:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pure motor hemiparesis",
"     </li>",
"     <li>",
"      Pure sensory stroke",
"     </li>",
"     <li>",
"      Ataxic hemiparesis",
"     </li>",
"     <li>",
"      Sensorimotor stroke",
"     </li>",
"     <li>",
"      Dysarthria-clumsy hand syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a group, the presence of these syndromes has a positive predictive value of 87 to 90 percent for detecting a radiological lacune [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], although some clinical syndromes are more predictive than others [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. Preceding TIAs and nonsudden onset may increase the positive predictive value for these lacunar syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/72\">",
"     72",
"    </a>",
"    ]. Predicted infarct locations in relation to clinical manifestations are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef67341 \" href=\"UTD.htm?36/36/37451\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Syndrome recognition may be more difficult in the hyperacute setting. A study of patients admitted within 6 hours of symptom onset reported only a 30 percent positive predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other syndromes that have not been studied in large clinical series but that may be related to lacunar infarcts are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef57474 \" href=\"UTD.htm?32/10/32939\">",
"     table 2",
"    </a>",
"    ). The syndrome of multiple subcortical infarcts will be discussed in addition to the five syndromes mentioned above since interest has arisen regarding whether this entity can cause dementia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pure motor hemiparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure motor hemiparesis is the most frequent syndrome in most clinical series, accounting for 45 to 57 percent of all lacunar syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31,65,74-76\">",
"     31,65,74-76",
"    </a>",
"    ]. It is characterized by weakness involving the face, arm, and leg on one side of the body in the absence of \"cortical\" signs (aphasia, agnosia, neglect, apraxia, or hemianopsia) or sensory deficit.",
"   </p>",
"   <p>",
"    The motor deficit may develop as a single event or, less frequently, be preceded by hemiplegic TIAs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/1\">",
"     1",
"    </a>",
"    ]. A series of the latter cases has been described as the \"capsular warning syndrome,\" which was found to be predictive of an acute internal capsule infarct on head CT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/77\">",
"     77",
"    </a>",
"    ]. Some of these cases may arise due to penetrating branch ischemia from a diseased \"parent\" vessel (MCA stem or basilar) causing intermittent and fluctuating symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pure sensory stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure sensory stroke is defined as numbness of the face, arm, and leg on one side of the body in the absence of motor deficit or \"cortical\" signs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/78\">",
"     78",
"    </a>",
"    ]. It is found in 7 to 18 percent of lacunar syndromes in case series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31,65,75,76\">",
"     31,65,75,76",
"    </a>",
"    ], but its prevalence is probably underestimated because many cases present as TIA and were not included in the series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ataxic hemiparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxic hemiparesis is responsible for 3 to 18 percent of lacunar syndromes in case series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31,65,75,76,79\">",
"     31,65,75,76,79",
"    </a>",
"    ]. Patients characteristically develop ipsilateral weakness and limb ataxia that is out of proportion to the motor deficit. Some patients may exhibit dysarthria, nystagmus, and gait deviation towards the affected side. As with other lacunar syndromes, the above-mentioned \"cortical\" signs are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sensorimotor stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensorimotor stroke is characterized by weakness and numbness of the face, arm, and leg on one side of the body in the absence of the aforementioned \"cortical\" signs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/80\">",
"     80",
"    </a>",
"    ]. It is responsible for 15 to 20 percent of lacunar syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31,65,75,76\">",
"     31,65,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensorimotor strokes arise from infarcts involving the posterolateral thalamus and posterior limb of the internal capsule. The exact vascular anatomy is debated. Theoretically, penetrating arteries from the posterior cerebral artery (PCA) supply the thalamus and the internal capsule is supplied from the lenticulostriate branches of the MCA. Occlusion of a single penetrating artery involving both arterial territories is difficult to implicate; the site of vascular occlusion was not identified in the original case description [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dysarthria-clumsy hand syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysarthria-clumsy hand syndrome is the least common of all lacunar syndromes in most case series, accounting for 2 to 6 percent of lacunar syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/31,65,75,76,81\">",
"     31,65,75,76,81",
"    </a>",
"    ]. Facial weakness, dysarthria, dysphagia, and slight weakness and clumsiness of one hand are characteristic. There are no sensory deficits or \"cortical\" signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Multiple subcortical infarcts and dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the first description of a lacunar syndrome in 1901 included a chronic neurologic course with episodes of mild hemiparesis progressing to abnormal gait, pseudobulbar signs, dysarthria, incontinence, and dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/3\">",
"     3",
"    </a>",
"    ]. Cases such as these have become rare, even in patients with multiple subcortical infarcts, and questions have been raised about whether the patients in the original description had unrecognized normal-pressure hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between subcortical strokes and cognitive deficits has been explained by interruption of neural connections with an indirect effect upon cortical metabolism and perfusion, so-called \"diaschisis.\" This hypothesis is supported by case series of CT-demonstrated subcortical infarcts presenting with transcortical aphasia or neglect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], as well as by functional studies using SPECT or positron emission tomography (PET) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study using PET compared cortical glucose metabolism in patients with dementia and subcortical infarcts, patients with subcortical strokes and normal cognitive function, and controls without cognitive impairment or stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/86\">",
"     86",
"    </a>",
"    ]. Global metabolism was impaired proportionally to cognitive decline, while regional right-sided frontal lobe metabolism was impaired in relationship to the presence of subcortical infarcts. No relationship was found between the number or location of the subcortical infarcts and the presence of cognitive impairment.",
"   </p>",
"   <p>",
"    Some but not all longitudinal studies have found an association between the development of new lacunes and cognitive decline [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. As an example, a prospective MRI study of 1015 patients without baseline dementia found that silent subcortical infarcts were associated with later development of dementia over four years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/87\">",
"     87",
"    </a>",
"    ]. Patients developing dementia more often had thalamic strokes at baseline and accumulated new subcortical lesions on a second MRI scan.",
"   </p>",
"   <p>",
"    Taken together, these findings indicate a potential mechanism for dementia in subcortical strokes and the need to develop more effective strategies to prevent the accumulation of silent subcortical infarcts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike our ability to visualize large vessel occlusion by vascular imaging (conventional angiography and CT or MR angiography), there is no clinically available method to confirm the presence of a single penetrator artery occlusion. Thus, the diagnosis of lacunar infarction in vivo relies upon finding a clinical syndrome that is consistent with the location of a small noncortical infarct seen on CT or MRI. Brain imaging with CT or MRI is also useful to exclude other potentially life-threatening diagnoses such as intracerebral hemorrhage or subdural hematoma. Investigation of the underlying stroke mechanism (eg, thrombosis versus embolism) is still indicated to exclude potentially correctable causes of recurrence.",
"   </p>",
"   <p>",
"    This section will primarily discuss the diagnostic tests used to confirm or exclude the clinical suspicion of a lacune (eg, CT, MRI, DWI). The evaluation of stroke mechanisms is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncontrast head CT is the initial imaging modality for most patients presenting with an acute stroke syndrome. CT has low sensitivity for detecting lacunes (30 to 44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/14,91\">",
"     14,91",
"    </a>",
"    ]. The sensitivity of CT for lacunes in the hyperacute phase (&lt;6 hours) has not been systematically studied, but is likely to be even lower; thus, a lacune seen on CT in this time window is more frequently chronic and not related to the clinical symptoms. CT also is limited in identifying posterior fossa infarcts and in defining the degree of cortical extension in subcortical infarcts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI has been extensively studied in lacunar infarcts. It has a higher sensitivity and specificity than CT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/91,92\">",
"     91,92",
"    </a>",
"    ], and is better for defining the exact anatomical localization. In one study, for example, MRI detected lacunar infarcts in 19 of 22 patients with compatible symptoms, compared with 11 found by CT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/92\">",
"     92",
"    </a>",
"    ]. A second report confirmed that MRI was superior to CT for detecting lacunes; the sensitivity of MRI was greatest for patients who presented with pure motor hemiparesis, detecting 85 percent of lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/91\">",
"     91",
"    </a>",
"    ]. MRI usually shows infarcts within 8 hours of symptom onset.",
"   </p>",
"   <p>",
"    An inherent difficulty of both CT and conventional MRI is the ability to differentiate between acute and chronic lesions. In one study, 16 percent of patients presenting with a lacunar syndrome had at least two lesions on conventional MRI that correlated with clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/14\">",
"     14",
"    </a>",
"    ]. Furthermore, in patients presenting with a lacunar syndrome, multiple chronic subcortical lesions are not rare, occurring in approximately 42 to 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/4,91\">",
"     4,91",
"    </a>",
"    ]. For these reasons, knowledge of possible lesion locations based upon neurologic findings is necessary before implicating a particular lesion found on MRI as responsible for the clinical symptoms (",
"    <a class=\"graphic graphic_table graphicRef67341 \" href=\"UTD.htm?36/36/37451\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Diffusion-weighted imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffusion-weighted imaging (DWI) is a fast MRI technique that demonstrates a hyperintense signal whenever there is an area of restricted water diffusion, as occurs during acute ischemia. DWI has the advantages of a higher sensitivity for acute lesions than T2-weighted MRI or FLAIR, ability to differentiate between acute and chronic lacunar infarcts, and ability to identify multiple acute infarcts potentially linked to embolic sources [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/37,93,94\">",
"     37,93,94",
"    </a>",
"    ]. In one study, 25 percent of DWI-hyperintense lacunar infarcts were either not seen or mistakenly called \"chronic\" on T2 or FLAIR imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/94\">",
"     94",
"    </a>",
"    ]. This finding suggests that patients require DWI to define the clinically appropriate infarct when multiple subcortical infarcts of various ages are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H10#H10\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The size of acute lacunar infarction is overestimated on DWI by approximately 40 percent when compared with final infarct size at 30 days or more after stroke onset on conventional MRI (T2 or FLAIR sequences) and CT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most situations, MRI with clinical correlation adequately defines the infarct location and excludes a cortically-based infarct. The extent of the remaining diagnostic investigation will depend upon the resources available and patient characteristics.",
"   </p>",
"   <p>",
"    Further testing is of low yield in patients suspected of having a lacunar infarction who have the typical risk factors for penetrating artery disease (eg, hypertension or diabetes mellitus), clinical neurologic findings suggestive of a typical lacunar syndrome, and a corresponding radiologic lacunar infarct (",
"    <a class=\"graphic graphic_table graphicRef67341 \" href=\"UTD.htm?36/36/37451\">",
"     table 1",
"    </a>",
"    ). On the other hand, more extensive investigation of potential embolic sources may be necessary in young patients with no cerebral risk factors and in patients with multiple lesions on DWI.",
"   </p>",
"   <p>",
"    Vascular imaging (CTA or MRA) can be performed at the same time as brain imaging (CT or MRI) to exclude occlusion of the parent feeding artery, a condition that can mimic a lacunar infarct [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/1,18,96\">",
"     1,18,96",
"    </a>",
"    ]. It is particularly important to perform intracranial vascular imaging in blacks and persons of Asian descent, since intracranial large artery occlusive disease is common in these populations. An alternative diagnostic test to exclude intracranial occlusive disease is transcranial Doppler (TCD), a technique that measures the blood flow velocities in the large intracranial arteries using an ultrasound probe placed over the orbit, temporal bone, and foramen magnum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H7#H7\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'CT angiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H15#H15\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'MR angiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H20#H20\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Transcranial Doppler'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no treatment proven to be beneficial specifically for lacunar infarction as opposed to ischemic stroke in general. Most clinical trials investigating stroke treatment and prevention have failed to adequately separate the lacunar infarct subpopulation. Nevertheless, the best available evidence suggests that intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    is beneficial for patients with lacunar stroke (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Thrombolytic therapy'",
"    </a>",
"    below). For secondary prevention, intensive medical treatment is recommended (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Prevention'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment and management of the acute phase (ie, the first few hours) of ischemic stroke is reviewed elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main goals in the initial phase of acute stroke management are to ensure medical stability, begin to uncover the pathophysiologic basis of the neurologic symptoms, and to determine whether patients with acute ischemic stroke are candidates to receive treatment with thrombolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Thrombolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials have shown that intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA) improves functional outcome from ischemic stroke and that benefits outweigh the risks for eligible patients who receive treatment within 4.5 hours of symptom onset (or within 4.5 hours of when the patient was last seen normal in cases when onset time is unknown). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H2#H2\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Intravenous thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subgroup analysis of trial data suggest that the benefit with thrombolysis is sustained in patients with lacunar stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/97\">",
"     97",
"    </a>",
"    ]. However, stroke subtype was classified mainly by clinical impression in the thrombolysis trials since vascular studies usually were not performed before treatment initiation. Thus, some patients with a large vessel or cardioembolic stroke mechanism (eg, those with proximal middle cerebral artery occlusion, good leptomeningeal collaterals, and recanalization after thrombolysis) may have been incorrectly classified as having a small vessel etiology. Nonetheless, until better data are available, we recommend that patients with lacunar syndromes be selected for thrombolysis according to current guidelines in the same way as patients with other subtypes of ischemic stroke (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombolytic therapy is associated with a 6 percent risk of symptomatic brain hemorrhage. Thus, its benefits must be viewed with caution in a condition with a relatively benign natural history (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Prognosis'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/97\">",
"     97",
"    </a>",
"    ]. This treatment option should be discussed with the patient and family in each individual case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Patients not eligible for thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acute ischemic stroke who are not eligible for thrombolytic therapy should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is generally not indicated for the management of acute lacunar stroke. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited efficacy of acute therapies for lacunar stroke suggests that secondary prevention should be a major focus of treatment. Intensive medical intervention and risk factor management, including antihypertensive, antiplatelet, and statin therapy, is recommended for most patients with ischemic stroke or transient ischemic attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link&amp;anchor=H32#H32\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other antiplatelet agents for preventing second strokes and mortality has been illustrated for stroke patients in general. Therefore, we recommend treatment with an antiplatelet agent for patients with a history of noncardioembolic stroke or transient ischemic attack of atherothrombotic, lacunar (small vessel occlusive type), or cryptogenic type. Aspirin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    are all acceptable options for preventing recurrent noncardioembolic ischemic stroke.",
"   </p>",
"   <p>",
"    Despite early enthusiasm, results from the SPS3 trial suggest that the long-term use of combined antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is harmful for patients with lacunar stroke because it leads to an increased risk of hemorrhage and death but does not reduce the risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/98\">",
"     98",
"    </a>",
"    ]. Therefore, it should",
"    <strong>",
"     not",
"    </strong>",
"    be employed for secondary prevention in this population in the absence of proven indications. The use of aspirin plus clopidogrel for prevention of different subtypes of ischemic stroke is discussed separately in detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link&amp;anchor=H640139#H640139\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Stroke subtypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    in Recurrent Stroke Study (WARSS) was a randomized, double-blind trial that investigated the benefits of aspirin (325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    compared with warfarin (international normalized ratio 1.4 to 2.8) in 2206 patients who had an ischemic stroke within the previous 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/99\">",
"     99",
"    </a>",
"    ]. Patients scheduled for carotid endarterectomy or who had a presumed cardioembolic source of stroke were not included. After two years of follow-up, there was",
"    <strong>",
"     no difference",
"    </strong>",
"    between the two groups in the prevention of recurrent ischemic stroke or death, or in the rate of major hemorrhage. More than one-half of the cohort (1237 patients) had a lacunar stroke as their initial event; this group also demonstrated no difference in outcome between warfarin and aspirin. Since warfarin does not appear to provide benefit over aspirin, and is more expensive and more difficult to manage, it does not appear to have a role in secondary prevention in patients who have had a lacunar infarct, other than in patients with a presumed embolic source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacunar infarcts have a better short term prognosis than infarcts due to other stroke mechanisms, at least up to one year after onset.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Oxfordshire Community Stroke Project, case fatality rates of 101 patients with lacunar infarction were 1 percent at one month and 10 percent at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/75\">",
"       75",
"      </a>",
"      ]. Recurrence rate was 12 percent in one year. Sixty-six percent of patients were capable of functional independence.",
"     </li>",
"     <li>",
"      A population-based study of 159 patients in Rochester found a case-fatality rate of 0 percent at one month and 3 percent at one year in patients with lacunar infarcts, compared with 14 and 28 percent, respectively, for nonlacunar infarcts [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the setting of a controlled clinical trial, 91 percent of patients with lacunar stroke from the placebo arm had a favorable outcome at three months, as defined by moderate to good recovery on the Glasgow Outcome Scale [",
"      <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/100\">",
"       100",
"      </a>",
"      ]. This contrasts with strokes due to large vessel atherosclerosis; only 55 percent of these patients had a favorable outcome at three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the longer-term prognosis after lacunar stroke may not differ greatly from nonlacunar stroke. This observation comes from a systematic review of 19 cohort studies involving 2402 patients with lacunar and 3462 patients with nonlacunar ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/30\">",
"     30",
"    </a>",
"    ]. The odds of death were significantly greater following nonlacunar than lacunar infarction at one month, 1 to 12 months, and one to five years (odds ratio [OR] 3.81, 2.32 and 1.77, respectively), although the difference gradually decreased. However, the odds of recurrent stroke were significantly greater for nonlacunar infarction only at one month (OR 2.11), and the difference in stroke recurrence between nonlacunar and lacunar groups was nonsignificant at 1 to 12 months and one to five years.",
"   </p>",
"   <p>",
"    Analogous findings were reported in a population-based study from Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with lacunar stroke (n = 491) had better five-year survival than patients with nonlacunar stroke (n = 2153), mainly due to lower mortality within the first year of follow-up for the lacunar stroke group. The lacunar group also had a lower average annual stroke recurrence rate within the first year. However, stroke recurrence and mortality rates were similar in the two groups from the second year through study completion at five years.",
"   </p>",
"   <p>",
"    Patients with lacunar infarction and more severe initial motor deficits have worse functional outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/59/4026/abstract/97,101\">",
"     97,101",
"    </a>",
"    ]. What is not known is whether patients with a lacunar infarct due to embolism or large vessel atherosclerosis obstructing the ostium of a penetrator branch have a different prognosis and response to therapy. As long as this question remains, investigation of the operating stroke mechanism remains important. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191951191\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lacunar infarcts are small (0.2 to 15 mm in diameter) noncortical infarcts caused by occlusion of a single penetrating branch of a large cerebral artery. These branches arise at acute angles from the large arteries of the circle of Willis, stem of the middle cerebral artery, and the basilar artery. Most lacunes occur in the basal ganglia (putamen, globus pallidus, thalamus, caudate), subcortical white matter (internal capsule and corona radiata), and pons. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Vascular anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several mechanisms for occlusion of small penetrator branches have been described (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lipohyalinosis of the penetrating arteries is the usual cause, particularly of smaller infarcts (3 to 7 mm in length).",
"     </li>",
"     <li>",
"      Microatheroma of the origin of the penetrating arteries coming off the middle cerebral artery stem, circle of Willis, or distal basilar or vertebral arteries. This mechanism has been proven pathologically by serial section for the basilar artery.",
"     </li>",
"     <li>",
"      In some cases, not proven pathologically, tiny emboli have been suspected as the cause of these small infarcts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lacunes account for 15 to 26 percent of ischemic strokes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two of the three described mechanisms for lacunar stroke are related to a chronic vasculopathy associated with systemic hypertension. Other likely risk factors include diabetes mellitus and possibly smoking. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors and associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 20 lacunar syndromes have been described. Five have been validated as being highly predictive for the presence of lacunes radiologically (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pure motor hemiparesis (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Pure motor hemiparesis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pure sensory stroke (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Pure sensory stroke'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ataxic hemiparesis (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Ataxic hemiparesis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Sensorimotor stroke (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Sensorimotor stroke'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Dysarthria-clumsy hand syndrome (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Dysarthria-clumsy hand syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      As a general rule, lacunar syndromes lack findings such as aphasia, agnosia, neglect, apraxia, or hemianopsia (so-called \"cortical\" signs). Monoplegia, stupor, coma, loss of consciousness, and seizures also are typically absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of lacunar infarction in vivo relies upon finding a clinical syndrome that is consistent with the location of a small noncortical infarct seen on CT or MRI. Brain imaging with CT or MRI is also useful to exclude other potentially life-threatening diagnoses such as intracerebral hemorrhage or subdural hematoma. Investigation of the underlying stroke mechanism (eg, thrombosis versus embolism) is still indicated to exclude potentially correctable causes of recurrence. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (recombinant tissue-type plasminogen activator or rt-PA) improves outcomes for patients with ischemic stroke in general if administered within 4.5 hours of symptom onset. The available evidence suggests that intravenous thrombolysis is beneficial for patients with lacunar stroke. Most patients with acute ischemic stroke who are not eligible for thrombolytic therapy should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lacunar infarcts have a better short term prognosis than infarcts due to other stroke mechanisms, at least up to one year after onset (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prognosis'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191951178\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Philip Kistler and Dr. C. Miller Fisher for their contributions to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/1\">",
"      Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982; 32:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/2\">",
"      Dechambre A. M&eacute;moire sur la curabilit&eacute; du ramollissement c&eacute;r&eacute;bral. Gaz Med Paris 1838; 6:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/3\">",
"      Marie P. Des foyers lacunaires de d&eacute;sint&eacute;gration et de diff&eacute;rents autres &eacute;tats cavitaires du cerveau. Rev M&eacute;d (Paris) 1901; 21:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/4\">",
"      FISHER CM. LACUNES: SMALL, DEEP CEREBRAL INFARCTS. Neurology 1965; 15:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/5\">",
"      Bamford JM, Warlow CP. Evolution and testing of the lacunar hypothesis. Stroke 1988; 19:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/6\">",
"      Bogousslavsky J. The plurality of subcortical infarction. Stroke 1992; 23:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/7\">",
"      Millikan C, Futrell N. The fallacy of the lacune hypothesis. Stroke 1990; 21:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/8\">",
"      Landau WM. Clinical neuromythology VI. Au clair de lacune: holy, wholly, holey logic. Neurology 1989; 39:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/9\">",
"      Futrell N. Lacunar infarction: embolism is the key. Stroke 2004; 35:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/10\">",
"      Davis SM, Donnan GA. Why lacunar syndromes are different and important. Stroke 2004; 35:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/11\">",
"      Norrving B. Lacunar infarction: embolism is the key: against. Stroke 2004; 35:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/12\">",
"      Baumgartner RW, Sidler C, Mosso M, Georgiadis D. Ischemic lacunar stroke in patients with and without potential mechanism other than small-artery disease. Stroke 2003; 34:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/13\">",
"      Caplan LR. Small deep brain infarcts. Stroke 2003; 34:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/14\">",
"      Hommel M, Besson G, Le Bas JF, et al. Prospective study of lacunar infarction using magnetic resonance imaging. Stroke 1990; 21:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/15\">",
"      Arboix A, Mart&iacute;-Vilalta JL, Garc&iacute;a JH. Clinical study of 227 patients with lacunar infarcts. Stroke 1990; 21:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/16\">",
"      Fisher CM. Capsular infarcts: the underlying vascular lesions. Arch Neurol 1979; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/17\">",
"      Feekes JA, Hsu SW, Chaloupka JC, Cassell MD. Tertiary microvascular territories define lacunar infarcts in the basal ganglia. Ann Neurol 2005; 58:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/18\">",
"      Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology 1989; 39:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/19\">",
"      Macdonald RL, Kowalczuk A, Johns L. Emboli enter penetrating arteries of monkey brain in relation to their size. Stroke 1995; 26:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/20\">",
"      Hart RG, Foster JW, Luther MF, Kanter MC. Stroke in infective endocarditis. Stroke 1990; 21:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/21\">",
"      Cacciatore A, Russo LS Jr. Lacunar infarction as an embolic complication of cardiac and arch angiography. Stroke 1991; 22:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/22\">",
"      Lee DK, Kim JS, Kwon SU, et al. Lesion patterns and stroke mechanism in atherosclerotic middle cerebral artery disease: early diffusion-weighted imaging study. Stroke 2005; 36:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/23\">",
"      Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/24\">",
"      Wardlaw JM. What causes lacunar stroke? J Neurol Neurosurg Psychiatry 2005; 76:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/25\">",
"      Wardlaw JM, Doubal F, Armitage P, et al. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann Neurol 2009; 65:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/26\">",
"      Tomimoto H, Akiguchi I, Suenaga T, et al. Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke 1996; 27:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/27\">",
"      Lammie GA, Brannan F, Wardlaw JM. Incomplete lacunar infarction (Type Ib lacunes). Acta Neuropathol 1998; 96:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/28\">",
"      Giwa MO, Williams J, Elderfield K, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology 2012; 78:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/29\">",
"      Lammie GA, Brannan F, Slattery J, Warlow C. Nonhypertensive cerebral small-vessel disease. An autopsy study. Stroke 1997; 28:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/30\">",
"      Jackson C, Sudlow C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain 2005; 128:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/31\">",
"      Chamorro A, Sacco RL, Mohr JP, et al. Clinical-computed tomographic correlations of lacunar infarction in the Stroke Data Bank. Stroke 1991; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/32\">",
"      Horowitz DR, Tuhrim S, Weinberger JM, Rudolph SH. Mechanisms in lacunar infarction. Stroke 1992; 23:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/33\">",
"      Tegeler CH, Shi F, Morgan T. Carotid stenosis in lacunar stroke. Stroke 1991; 22:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/34\">",
"      Sacco SE, Whisnant JP, Broderick JP, et al. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991; 22:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/35\">",
"      Inzitari D, Eliasziw M, Sharpe BL, et al. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. North American Symptomatic Carotid Endarterectomy Trial Group. Neurology 2000; 54:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/36\">",
"      Tejada J, D&iacute;ez-Tejedor E, Hern&aacute;ndez-Echebarr&iacute;a L, Balboa O. Does a relationship exist between carotid stenosis and lacunar infarction? Stroke 2003; 34:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/37\">",
"      Ay H, Oliveira-Filho J, Buonanno FS, et al. Diffusion-weighted imaging identifies a subset of lacunar infarction associated with embolic source. Stroke 1999; 30:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/38\">",
"      Wessels T, R&ouml;ttger C, Jauss M, et al. Identification of embolic stroke patterns by diffusion-weighted MRI in clinically defined lacunar stroke syndromes. Stroke 2005; 36:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/39\">",
"      Sacco S, Marini C, Totaro R, et al. A population-based study of the incidence and prognosis of lacunar stroke. Neurology 2006; 66:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/40\">",
"      Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999; 30:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/41\">",
"      Woo D, Gebel J, Miller R, et al. Incidence rates of first-ever ischemic stroke subtypes among blacks: a population-based study. Stroke 1999; 30:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/42\">",
"      Kubo M, Kiyohara Y, Ninomiya T, et al. Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology 2006; 66:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/43\">",
"      Bezerra DC, Sharrett AR, Matsushita K, et al. Risk factors for lacune subtypes in the Atherosclerosis Risk in Communities (ARIC) Study. Neurology 2012; 78:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/44\">",
"      Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999; 159:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/45\">",
"      Eikelboom JW, Hankey GJ, Anand SS, et al. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/46\">",
"      Iso H, Moriyama Y, Sato S, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004; 109:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/47\">",
"      Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2007; 78:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/48\">",
"      Jackson CA, Hutchison A, Dennis MS, et al. Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy? Stroke 2010; 41:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/49\">",
"      Knopman DS, Penman AD, Catellier DJ, et al. Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. Neurology 2011; 76:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/50\">",
"      Lodder J, Bamford JM, Sandercock PA, et al. Are hypertension or cardiac embolism likely causes of lacunar infarction? Stroke 1990; 21:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/51\">",
"      van Dijk EJ, Prins ND, Vermeer SE, et al. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004; 55:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/52\">",
"      de Leeuw FE, Richard F, de Groot JC, et al. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004; 35:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/53\">",
"      Jannes J, Hamilton-Bruce MA, Pilotto L, et al. Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke 2004; 35:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/54\">",
"      Hassan A, Lansbury A, Catto AJ, et al. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. J Neurol Neurosurg Psychiatry 2002; 72:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/55\">",
"      Richards A, van den Maagdenberg AM, Jen JC, et al. C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007; 39:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/56\">",
"      Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy. A new hereditary syndrome. Ophthalmology 1988; 95:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/57\">",
"      Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/58\">",
"      Terwindt GM, Haan J, Ophoff RA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. Brain 1998; 121 ( Pt 2):303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/59\">",
"      Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 2009; 360:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/60\">",
"      Vahedi K, Massin P, Guichard JP, et al. Hereditary infantile hemiparesis, retinal arteriolar tortuosity, and leukoencephalopathy. Neurology 2003; 60:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/61\">",
"      Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006; 354:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/62\">",
"      Sibon I, Coupry I, Menegon P, et al. COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann Neurol 2007; 62:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/63\">",
"      Vahedi K, Boukobza M, Massin P, et al. Clinical and brain MRI follow-up study of a family with COL4A1 mutation. Neurology 2007; 69:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/64\">",
"      Steinke W, Ley SC. Lacunar stroke is the major cause of progressive motor deficits. Stroke 2002; 33:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/65\">",
"      Gan R, Sacco RL, Kargman DE, et al. Testing the validity of the lacunar hypothesis: the Northern Manhattan Stroke Study experience. Neurology 1997; 48:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/66\">",
"      Boiten J, Lodder J. Lacunar infarcts. Pathogenesis and validity of the clinical syndromes. Stroke 1991; 22:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/67\">",
"      Gorman MJ, Dafer R, Levine SR. Ataxic hemiparesis: critical appraisal of a lacunar syndrome. Stroke 1998; 29:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/68\">",
"      Melo TP, Bogousslavsky J, van Melle G, Regli F. Pure motor stroke: a reappraisal. Neurology 1992; 42:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/69\">",
"      Toni D, Del Duca R, Fiorelli M, et al. Pure motor hemiparesis and sensorimotor stroke. Accuracy of very early clinical diagnosis of lacunar strokes. Stroke 1994; 25:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/70\">",
"      Moulin T, Bogousslavsky J, Chopard JL, et al. Vascular ataxic hemiparesis: a re-evaluation. J Neurol Neurosurg Psychiatry 1995; 58:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/71\">",
"      Kim JS. Pure sensory stroke. Clinical-radiological correlates of 21 cases. Stroke 1992; 23:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/72\">",
"      Herv&eacute; D, Gautier-Bertrand M, Labreuche J, et al. Predictive values of lacunar transient ischemic attacks. Stroke 2004; 35:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/73\">",
"      Toni D, Iweins F, von Kummer R, et al. Identification of lacunar infarcts before thrombolysis in the ECASS I study. Neurology 2000; 54:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/74\">",
"      FISHER CM, CURRY HB. PURE MOTOR HEMIPLEGIA OF VASCULAR ORIGIN. Arch Neurol 1965; 13:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/75\">",
"      Bamford J, Sandercock P, Jones L, Warlow C. The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. Stroke 1987; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/76\">",
"      Schonewille WJ, Tuhrim S, Singer MB, Atlas SW. Diffusion-weighted MRI in acute lacunar syndromes. A clinical-radiological correlation study. Stroke 1999; 30:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/77\">",
"      Donnan GA, O'Malley HM, Quang L, et al. The capsular warning syndrome: pathogenesis and clinical features. Neurology 1993; 43:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/78\">",
"      FISHER CM. PURE SENSORY STROKE INVOLVING FACE, ARM, AND LEG. Neurology 1965; 15:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/79\">",
"      FISHER CM, COLE M. HOMOLATERAL ATAXIA AND CRURAL PARESIS: A VASCULAR SYNDROME. J Neurol Neurosurg Psychiatry 1965; 28:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/80\">",
"      Mohr JP, Kase CS, Meckler RJ, Fisher CM. Sensorimotor stroke due to thalamocapsular ischemia. Arch Neurol 1977; 34:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/81\">",
"      Fisher CM. A lacunar stroke. The dysarthria-clumsy hand syndrome. Neurology 1967; 17:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/82\">",
"      Bogousslavsky J, Regli F, Assal G. The syndrome of unilateral tuberothalamic artery territory infarction. Stroke 1986; 17:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/83\">",
"      Bogousslavsky J, Regli F, Uske A. Thalamic infarcts: clinical syndromes, etiology, and prognosis. Neurology 1988; 38:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/84\">",
"      Perani D, Vallar G, Cappa S, et al. Aphasia and neglect after subcortical stroke. A clinical/cerebral perfusion correlation study. Brain 1987; 110 ( Pt 5):1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/85\">",
"      Pappata S, Mazoyer B, Tran Dinh S, et al. Effects of capsular or thalamic stroke on metabolism in the cortex and cerebellum: a positron tomography study. Stroke 1990; 21:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/86\">",
"      Kwan LT, Reed BR, Eberling JL, et al. Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol 1999; 56:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/87\">",
"      Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/88\">",
"      Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 2005; 65:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/89\">",
"      van Dijk EJ, Prins ND, Vrooman HA, et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008; 39:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/90\">",
"      Jokinen H, Gouw AA, Madureira S, et al. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011; 76:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/91\">",
"      Arboix A, Mart&iacute;-Vilalta JL, Pujol J, Sanz M. Lacunar cerebral infarct and nuclear magnetic resonance. A review of sixty cases. Eur Neurol 1990; 30:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/92\">",
"      Brown JJ, Hesselink JR, Rothrock JF. MR and CT of lacunar infarcts. AJR Am J Roentgenol 1988; 151:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/93\">",
"      Singer MB, Chong J, Lu D, et al. Diffusion-weighted MRI in acute subcortical infarction. Stroke 1998; 29:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/94\">",
"      Oliveira-Filho J, Ay H, Schaefer PW, et al. Diffusion-weighted magnetic resonance imaging identifies the \"clinically relevant\" small-penetrator infarcts. Arch Neurol 2000; 57:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/95\">",
"      Koch S, McClendon MS, Bhatia R. Imaging evolution of acute lacunar infarction: leukoariosis or lacune? Neurology 2011; 77:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/96\">",
"      Khan A, Kasner SE, Lynn MJ, et al. Risk factors and outcome of patients with symptomatic intracranial stenosis presenting with lacunar stroke. Stroke 2012; 43:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/97\">",
"      Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/98\">",
"      SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/99\">",
"      Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/100\">",
"      Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998; 279:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/59/4026/abstract/101\">",
"      Samuelsson M, S&ouml;derfeldt B, Olsson GB. Functional outcome in patients with lacunar infarction. Stroke 1996; 27:842.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1136 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4026=[""].join("\n");
var outline_f3_59_4026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H191951191\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VASCULAR ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS AND ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypertension and diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pure motor hemiparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pure sensory stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ataxic hemiparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sensorimotor stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dysarthria-clumsy hand syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Multiple subcortical infarcts and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Diffusion-weighted imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Patients not eligible for thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191951191\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191951178\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1136|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/38/18023\" title=\"diagnostic image 1\">",
"      Lacunar infarcts MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1136|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/6/42086\" title=\"figure 1\">",
"      Vascular anatomy lacunes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/54/25453\" title=\"figure 2\">",
"      Time course lacunar stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/36/37451\" title=\"table 1\">",
"      Lacunar syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/10/32939\" title=\"table 2\">",
"      Other lacunar syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 3\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=related_link\">",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_59_4027="Killip classification of acute MI";
var content_f3_59_4027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Killip classification of acute myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Class I",
"       </td>",
"       <td>",
"        No evidence of heart failure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\">",
"        Class II",
"       </td>",
"       <td>",
"        Findings consistent with mild to moderate heart failure (S3 gallop, lung rales less than one-half way up the posterior lung fields, or jugular venous distension)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\">",
"        Class III",
"       </td>",
"       <td>",
"        Overt pulmonary edema",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\">",
"        Class IV",
"       </td>",
"       <td>",
"        Cardiogenic shock",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4027=[""].join("\n");
var outline_f3_59_4027=null;
var title_f3_59_4028="Oral abx paronychia";
var content_f3_59_4028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric therapy for paronychia due to presumed oral flora",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Agent of choice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxicillin - clavulanate (875/125 mg twice daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Alternate empiric regimens include:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       One of the following agents with activity against",
"       <em>",
"        Eikenella",
"       </em>",
"       :",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Doxycycline* (100 mg twice daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Trimethoprim-sulfamethoxazole* (1 double strength tablet twice daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penicillin VK (500 mg four times daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cefuroxime (500 mg twice daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Fluoroquinolones (one of the following):",
"       </p>",
"       <p>",
"        &bull; Ciprofloxacin (500 to 750 mg twice daily)",
"       </p>",
"       <p>",
"        &bull; Moxifloxacin (400 mg once daily)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       <span class=\"red\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       One of the following agents with anaerobic activity:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Metronidazole (500 mg three times daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clindamycin* (450 mg three times daily)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       The following agents have poor activity against",
"       <em>",
"        Eikenella",
"       </em>",
"       and should be avoided:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cephalexin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dicloxacillin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Erythromycin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Also active against MRSA (check susceptibility testing).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4028=[""].join("\n");
var outline_f3_59_4028=null;
var title_f3_59_4029="Causes abd pain";
var content_f3_59_4029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of causes of abdominal pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Visceral",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          1. Mechanical obstruction of hollow viscera",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          a. Obstruction of the small or large intestine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          b. Obstruction of the biliary tree",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          c. Obstruction of the ureter",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          2. Distention of visceral surfaces, eg, hepatic or renal capsules",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          3. Vascular disturbances",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          a. Embolism or thrombosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          b. Vascular rupture",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          c. Pressure or torsional occlusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          d. Sickle cell anemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          4. Referred from non-abdominal viscera",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          a. Thorax, eg, pneumonia, referred pain from coronary occlusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          5. Metabolic causes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          a. Black widow spider bite",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          b. Lead poisoning and others",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          c. Uremia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          b. Diabetic ketoacidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          c. Porphyria",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          d. Allergic factors (C'1 esterase inhibitor deficiency)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Somatic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          1. Parietal peritoneal inflammation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          a. Bacterial contamination, eg, perforated appendix, pelvic inflammatory disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          b. Chemical irritation, eg, perforated ulcer, pancreatitis, mittelschmerz",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          2. Abdominal wall",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          a. Distortion or traction of mesentery",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          b. Trauma or infection of muscles",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          3. Spine, eg, radiculitis from arthritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_single\">",
"          4. Neurogenic causes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          a. Tabes dorsalis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          b. Herpes zoster",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          c. Causalgia and others",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          d. Functional",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Howard, FM. Acute Abdominal Pain. In: Primary Care for Women., Leppert, PC, Peipert, P (Eds), Lippincott, Williams and Wilkins 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4029=[""].join("\n");
var outline_f3_59_4029=null;
var title_f3_59_4030="Drug and toxin induced ocular findings";
var content_f3_59_4030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced ocular abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Mydriasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ephedrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methylphenidate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cathinones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Atropine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Scopolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiparkinson agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Muscle relaxants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antispasmodics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines (some)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Plants (with belladonna alkaloids)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Hallucinogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            LSD",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mescaline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Psilocybin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Designer amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Glutethimide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            MAOIs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nicotine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Serotonin syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug withdrawal states",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opioids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Heroin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Morphine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hydromorphone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oxycodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hydrocodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Codeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Propoxyphene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sedative-hypnotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Benzodiazepines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Alcohols (with deep coma)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Zolpidem and related medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nerve agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphate insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamate insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pilocarpine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Edrophonium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Physostigmine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympatholytics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clonidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oxymetazoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tetrahydrazoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phencyclidine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nystagmus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phencyclidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic alcohols",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scorpion stings&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Strychnine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            MAOIs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serotonin syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ketamine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4030=[""].join("\n");
var outline_f3_59_4030=null;
var title_f3_59_4031="Intraoperative PTH dynamics";
var content_f3_59_4031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Intraoperative parathyroid hormone (PTH) dynamics during parathyroidectomy for sporadic primary hyperparathyroidism in two successfully treated patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 364px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The pre-excision PTH level has increased when compared to the pre-incision sample due to manipulation of the abnormal gland during dissection. In this case, if the pre-excision sample was not collected, the intraoperative parathyroid hormone monitoring (IPM) criterion would not have been met in 10 minutes.",
"    <br>",
"     (B) The pre-excision PTH level has already decreased when compared to the pre-incision sample due to early devascularization of the abnormal gland. In this case, if the pre-incision sample was not collected, the IPM criterion would not have been met in 10 minutes.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_59_4031=[""].join("\n");
var outline_f3_59_4031=null;
